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ABSTRACT
Transitions within opioid therapy and their impact on morbidity,
healthcare utilization, and costs
James Douglas Thornton
In the United States (US), chronic non-cancer pain (CNCP) is prevalent among adults
with costs exceeding half a billion dollars annually1 and can be especially burdensome for
working age adults due to lost productivity and negative impacts on quality of life.2-6 An
estimated 43% of adults experience pain, and the majority of them are working age (22-64
years).6 Despite lack of robust evidence on the efficacy and effectiveness of opioids relieving
CNCP,7,8 and currently-available effective non-opioid treatments,9 many patients still receive
opioid therapy. Opioids are associated with significant negative health consequences up to and
including addiction to opioids which further increases their risk for overdose and death.10
Effective clinical, policy, and community responses to solve the opioid epidemic focus on a
continuum beginning with appropriate initiation of opioids and ending with harm reduction
efforts.11-17 The first step is the appropriate initiation of opioids because as many as 46% of
adults who were initiated on opioids transition into chronic opioid users.18 Chronic opioid
therapy (COT) can exacerbate current conditions and lead to development of new chronic
physical and mental health conditions, and other opioid-related adverse effects including
overdose.7,19-22 These negative consequences related to opioids lead to high economic burden
through increased emergency room, inpatient, and other healthcare utilization and healthcare
expenditures.19-24 Analysis of COT and its economic burden is especially important among
working-age adults who receive opioids more frequently when they experience pain.25
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This study was conducted to (1) assess factors which predict the transition to COT, (2)
estimate the changes in healthcare utilization and expenditure associated with the transition to
COT, and (3) to identify educational strategies that can be used to fill knowledge gaps about
opioids, naloxone, and opioid use disorder treatment medications for a group of healthcare
professionals who are well suited to help alleviate the opioid epidemic.
First, we identified leading predictors associated with incident COT among adults
without cancer in the US using a 10% random sample of working-age adults (age 28-63 years)
insured in commercial plans, who were initiated on opioids between January 2007 through May
2015. The four leading predictors of COT were opioid duration-of-action [AOR= 12.28; 95%CI=
8.06-18.72], parent opioid tramadol vs. codeine, [AOR= 7.26; 95%CI= 5.20-10.13], the presence
of conditions highly likely to cause chronic pain [AOR= 5.47; 95%CI= 3.89-7.68] and drug use
disorders [AOR= 4.02; 95%CI= 2.53-6.40]. Next, using the same data source, we assessed the
association between transitioning from incident opioid use to chronic opioid therapy (COT), on
the trajectories of health utilization and expenditures. Patients who transitioned to COT were
more likely to use inpatient services [AOR=1.11, 95%CI(1.01,1.21)] compared to those who did
not transition. While expenditures peaked during the transition period (t4) for all users,
differences in unadjusted average, 120-day expenditures between COT and no COT users were
highest in t4 for total ($4,607) and inpatient expenditures ($2,453). COT users had significantly
higher total (β=0.183, p<0.01) and inpatient expenditures (β=0.448, p<0.001). For these first two
aims, we found that initial opioid regimen characteristics are powerful predictors of COT, and
the period after incident opioid prescription, but before COT, is an important time for
intervention for payers.
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Patients who have already transitioned to COT, or even opioid misuse or abuse need
increased levels of care. The third aim sought to identify educational strategies related to opioids,
buprenorphine products, and naloxone, for pharmacists, and to determine geographic locations to
reduce the risk of opioid overdose in West Virginia (WV). A mixed-methods design included a
prospective cross-sectional survey administered in two phases to increase coverage of the whole
state, then results were weighted based on a census of all pharmacists in WV. Most pharmacists
perceived high risk of opioid misuse in their area and high perceived efficacy about naloxone as
a treatment for opioid overdose, but many did not feel comfortable selling naloxone. Opioid
attitudes significantly differed between pharmacists in different EPPM-assigned categories.
Filling practices differed; 73% stocked buprenorphine/naloxone and only 58% stocked
buprenorphine. Pharmacists with higher perceived efficacy of buprenorphine products were more
likely to be willing to fill non-local prescriptions. County-level disparities between actual and
perceived risk for opioid misuse were observed. In the qualitative evaluation, pharmacists listed
many barriers to caring for patients prescribed opioids or buprenorphine products. By tailoring
educational strategies and objectives to pharmacists in specific geographic locations, more
effective CPE can be delivered to community pharmacists in WV to improve access to naloxone
and buprenorphine products as well as improve their understanding of addiction and
psychosocial treatments.
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CHAPTER 1
1
1.1

Introduction
Background and Need for Study
Pain is classified as acute or chronic with chronic pain defined as pain beyond the time of

normal tissue healing, or three months.26,27 An estimated 43% of adults experience pain of any
kind in the past 12 months, and the majority of them are working age with an adjusted mean age
of 44 years.6 Chronic pain can be especially burdensome for the working age population due to
lost productivity and negative impacts on quality of life.2-6 The most common source of chronic
pain for those without cancer, referred to as chronic noncancer pain (CNCP), is musculoskeletal
in origin (joint or back pain), but other sources (e.g. migraine or neuropathic) are also
prevelant.6,28
CNCP can be managed using many different therapy regimens including pharmacologic
options (non-opioid pharmacotherapy and opioid therapy) and non-pharmacologic options which
have been shown effective (e.g. electrical stimulation, physical therapy, psychological
interventions, or exercise).7,9,29 CNCP is treated with opioids despite lack of robust evidence on
the efficacy and effectiveness of COT. Opioids have been recommended to only be used after
considering a non-opioid analgesic regimen.7 However, in 2012, prescriptions for opioid
analgesics in the United States peaked at 259 million30 and nearly one in five patients who
presented to their healthcare provider with a painful condition in 2010 were prescribed an
opioid.31 Although opioids can treat pain effectively in the short term, the long term effectiveness
is not established,7,8 yet 35% of adults received opioids for CNCP.10
Many adults with CNCP who were initiated on opioids transition into COT with adverse
health consequences; however, research on transitions into long-term opioid use among working
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age adults is lacking. Although the benefits of long-term opioid therapy (over 1 year) have not
been sufficiently established in terms of pain, physical functioning, or health-related quality of
life, 7 the percentage of adults who transition to COT varies widely- from as low as 5% to as high
as 46%.10,18 While there is substantial published literature on COT among elderly (age > 65
years),32-34 factors affecting how working-age adults with CNCP transition into COT are less
well understood.7,35
Chronic opioid therapy can have serious health consequences. For example, compared to
other non-opioid regimens, opioid regimens have been shown to have higher risk for an opioid
abuse or dependence diagnosis, increased cardiovascular events, endocrinologic harms (e.g.
androgen deficiency), factures, and acute trauma including vehicle crashes.7,29Other opioidrelated side effects (e.g. xerostomia, nausea, constipation, pruritus, dizziness, vomiting,
drowsiness) can negatively affect patient’s quality of life.7,36-40 Many opioid users progress to be
diagnosed with an opioid use disorder which further increases their risk for overdose and
death.7,10 In a claims-based analysis of those with CNCP, it was reported that long-term opioid
users were more likely to be diagnosed with opioid use disorder compared to those not
prescribed opioids.10 Furthermore, COT can exacerbate current conditions and lead to
development of new chronic physical and mental health conditions.7,19-22 As identified in
multiple large patient populations, patients with COT (mean ages ranged from 44.6 (SD=15.1) to
55.4 (13.0) years) were more likely to develop depression compared to those without opioids
(HR=1.35, 95%CI=1.26-1.44 in the Veterans cohort to 2.05 (1.75-2.40) in an cohort of enrollees
in an HMO network). 41
Preventing inappropriate initiation and utilization of opioid medications is the shared
responsibility of patients, prescribers, policy-makers, and healthcare payers.7,42 The first step
2

towards preventing opioid misuse and/or addiction is appropriate initiation of opioids because
persistence in patients with COT is so high.18 In a prospective study, 46% of adults who were
initiated on opioids transistioned into chronic opioid users.18 One way to aid early identification
of individuals at high risk for transitioning to COT is through predictive modeling which can be
used to augment clinicians’ knowledge.43,44 Predictive modeling allows for the inclusion of vast
amounts of data coming from previously treated patients and can also be applied to real-time
data customized to specific regions, providers, or insurers.43,44 Early identification of patients
with certain modifiable risk factors (e.g. opioid dose, opioid duration of action, polypharmacy,
and number of concomitant pain medications) can help inform early risk mitigation efforts which
have shown some efficacy at preventing opioid-related adverse events including overdose and
death.7,45,46 Current CDC opioid prescribing guidelines recommend follow-up earlier than three
months (before the transition to COT) to increase the likelihood of preventing opioid-related
adverse events.7 This recommendation was made in light of findings that transitioning to COT
dramatically increases the risk for opioid use disorders, but there is not enough evidence to
recommend monitoring intervals or how monitoring should be performed.7,10
Transition into COT can lead to significant economic consequences, however, robust
evidence on the effect of transitions to COT on economic consequences is not available. Every
year, an estimated $78 billion is spent on adverse consequences of opioids including potential
misuse, abuse, and adverse effects.24 Adverse health effects due to prescription opioids often
result in increased healthcare utilization and expenditures of working Americans.2-5 For example,
prescription opioids accounted for over 14,000 overdose deaths, in 2014.47 This can lead to high
economic burden through increased emergency room, inpatient, and other healthcare utilization
and healthcare expenditures.19-24 Drug overdoses due to opioids accounted for nearly 7,000 ED
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visits daily22 and the number of emergency department visits due to opioids have doubled from
2004 to 2011.19 Over the past two decades, the number of hospital discharges associated with
opioid overdoses increased by over two and a half times.21 At the patient-level, patients who
were prescribed opioids had higher emergency department, inpatient, and outpatient visits, as
well as increased analgesic use, out-of-pocket spending, and third-party spending compared to
patients not prescribed opioid medications.19,23,48,49
However, studies that systematically determined the effect of the transition from acute to
COT has on healthcare utilization and expenditures are lacking.10,20 One study using data from a
large managed care organization reported that healthcare utilization and expenditures were
higher among long-term opioid users compare to other opioid users.20This study has many
serious limitations such as use of non-standard definition of long-term opioid therapy and opioid
regimen characteristics. The definitions for chronic users (>182 days) were different than the
Agency for Healthcare Research and Quality (AHRQ) and CDC definition of >90 days (3
months)7,8, as well as opioid regimen characteristics being categorized as strong or weak.20
Categorizing opioid regimens based on being “strong” or “weak” does not incorporate potency,
and if opioids are prescribed in equipotent doses, they are more or less, equally effective.7,26 The
proposed study will address the serious limitations of the prior literature and analyze the impact
of transitions from initiation of opioids to COT on the economic burden in a nationallyrepresentative sample of working age adults using definitions concordant with definitions used
by CDC, AHRQ, and current literature.7,8,50,51
While reducing the likelihood of prescribing poorly monitored or inappropriate COT is a
necessary long-term goal, in the short-term we still need community-based harm reduction
strategies to prevent unintentional injuries and deaths.46,52-54 Unintentional opioid overdose
4

deaths can be limited by co-prescribing naloxone to patients with high risk COT.7,15 In addition
to prescribers, current policy and intervention efforts have focused on preventing overdose and
death (i.e. harm reduction).11-17 Naloxone has been approved in many forms (e.g. intranasal,
intravenous) and can completely reverse the immediate risks of opioid overdose and prevent
deaths due to opioid overdose.55,56 State policies are changing to increase accessibility to patients
as well as their friends, family members, and caregivers. In states where naloxone is already
available in community pharmacies, pharmacists are helping to prevent opioid-related overdose
deaths by dispensing naloxone.57 Even with these policy changes, providing naloxone within the
community is a voluntary act, and needs buy-in from community pharmacists to be effectively
implemented.
Pharmacists working in community pharmacies are the most widely available healthcare
professionals58 and the gatekeepers to prescription opioids as well as the medications used to
treat opioid use disorder. As dispensers, they typically function in their gatekeeper position while
possessing little clinical or diagnostic information on the intended indication for opioid use.59
Despite having little information, pharmacists remain legally accountable to only dispense
controlled substances for legitimate medical purposes and to reduce diversion.60 Even if the
information on potentially inappropriate prescribing is available to the pharmacists (e.g. from a
perception drug monitoring program) the interventions a pharmacist can make are limited.54 This
obligation has other implications as pharmacists may feel the need to stock less and scrutinize
more, especially when they feel uncertain about the legitimacy of a controlled substance
prescription.61 To help alleviate these feelings, provider education must be made available to
help pharmacists do their jobs more effectively.62 Under ideal circumstances, their provision of
naloxone is performed as one component of a larger public health mission that includes health
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promotion, injury prevention, and harm reduction.52 Community pharmacies throughout the
country have taken on naloxone distribution as part of the public health mission to prevent
deaths.52 Pharmacists are providing naloxone to the community in unique ways and their legal
responsibilities are in a state of change.16,17,52,63,64
West Virginia (WV) is an appropriate state to evaluate the capacity of community
pharmacies to provide naloxone due to its reliance on community pharmacies to provide access
to healthcare and its current high levels of opioid abuse and deaths.47,65 In 2015, WV led the US
with 35.5 deaths per 100,000 inhabitants – twice the national average.47 Lynne Fruth, owner of
20 community pharmacies in WV supported providing naloxone by stating, “If you live to fight
another day, you have another chance at recovery.”66 States which have been most burdened by
the opioid epidemic have used community pharmacists to increase access to naloxone.17,67,68 For
example, Kentucky (24.7 drug overdose deaths per 100,000 inhabitants) passed legislation for
pharmacists to provide naloxone in the community in 2015 and the state agencies provide
education materials tailored to pharmacists in their state.64 Despite the anecdotal successes,46,53
the true societal impact of naloxone in a community will be determined in the coming months
and years.
To optimize the process of providing naloxone to the community in WV requires the
educational needs of pharmacists to be evaluated as well as their individual perceptions of
perceived opioid efficacy, perceived naloxone efficacy, and willingness to stock naloxone. From
this specific harm reduction strategy to improving initiation of COT, elucidating the transitions
in opioid use is critical to understanding the opioid epidemic more fully. The findings from this
study will provide valuable information to clinicians, insurers, policy makers, and researchers
about these transitions and indicate better options for clinical practice and public health policy.
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1.2

Specific Aims
The specific aims are guided by the adapted Continuum of Care for Opioid Misuse

developed by the Opioid Taskforce for the Alcohol and Drug Abuse Institute at the University of
Washington.42 The aims of this study are to evaluate the transitions of care a patient may
experience in their treatment with COT which are all conceptually linked using this framework
(Figure 1.1).
AIM 1: Identify leading predictors of transitioning from acute to COT among working age adults
without cancer with advanced predictive modeling techniques using a nationally representative
sample of working-age adults.
Hypothesis 1: Modifiable factors related to opioid regimen such as dose and duration of
action, polypharmacy, and concomitant pain medications, will be the leading predictors
of COT in working age adults.
AIM 2: Analyze the effect of transitions from incident acute opioid therapy to incident COT on
the trajectories of healthcare utilization and expenditures using a nationally representative
sample of working-age adults.
Hypothesis 2: The growth in utilization and expenditures over time will be higher among
adults who transitioned to COT as compared to adults who did not transition into COT,
even after adjusting for initial opioid regimen characteristics, comorbidities, and
demographic information.
AIM 3: Evaluate the potential for harm reduction capacity, in terms of naloxone distribution
from community pharmacies, of a high abuse state with assessment of perceptions, behaviors,
and educational needs of pharmacists licensed and working in West Virginia.
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1.3

Innovation
Identification of leading, modifiable predictors using routinely collected data such as

insurance claims and electronic heath records to identify patients at high risk for with incident
COT will allow clinicians, policy makers, insurers and other stakeholders develop strategies to
intervene early for patients. WV is the only state situated entirely within Appalachia, and home
to people who rank among the oldest, poorest, and least-educated in the US, who face limited
health care access due to geographic isolation, and have among the highest prevalence of most
health-related risk factors in the nation. With the recent passage of a WV law allowing
pharmacists the opportunity to act as naloxone providers, effective educational strategies are
needed quickly.69 This study can make a significant difference towards solving the opioidepidemic in the state. Education has been identified as a key component in reducing opioid abuse
in the United States.7,62,70 The Extended Parallel Process Model (EPPM) will be used to assess
educational needs and provide a framework for categorizing types of pharmacists based on their
perceptions relating to opioid use, misuse, and abuse. EPPM is used for the first time to develop
public communications for pharmacists. WV is well-known for its limited healthcare
infrastructure and pharmacists are well-positioned to respond to the opioid crisis. Evaluating the
perceptions and actions of the community pharmacists being tasked with providing naloxone in
their pharmacies has been identified as an important next step by clinicians and promulgated by
the American Pharmacists Association.63
1.4

Impact
By predicting incident COT, clinicians and insurers can personalize treatment options

including non-opioid regimens for adults at high risk for COT. By tracking the economic burden
of opioid use from initiation to COT, payers can identify crucial time-windows for designing and

8

implementing value-based designs with financial incentives and disincentives to prevent
expensive COT and its complications. Further, by evaluating community pharmacists’ readiness
to support harm-reduction efforts will help regulators, policy makers, and patients in
implementation of policy around co-prescription of naloxone in community-pharmacies.

9

Figure 1.1 Adapted continuum of care for opioid misuse42
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CHAPTER 2
2

Predictors of transitioning to incident chronic opioid therapy among working-aged
adults

2.1

Abstract

Background: Opioids are being prescribed and used for chronic non-cancer pain at prolific rates
in the United States over the last two decades. Patients who transition to incident chronic opioid
therapy (COT) are at higher risk for significant, negative health consequences including
cardiovascular risk, endocrine disorders, opioid use disorder, and death. Objective: The objective
of this study was to identify leading predictors associated with incident COT among adults
without cancer in the US. Design: Retrospective observational cohort with claims from a
nationally-representative sample of adults enrolled in commercial insurance plans. Standard
parametric (logistic regressions) and non-parametric methods based on decision tree were used
for prediction. For easier comparison with published literature, we also present adjusted odds
ratios (AOR) and 95% confidence intervals (CI). Participants: A 10% random sample of
working-age adults (age 28-63 years) insured in commercial plans, without cancer and who were
initiated on opioids between January 2007 through May 2015. Main Measures: Transition to
incident COT (at least 90 days of opioids claimed within 120 days) after initiation of opioids.
Predictive models included a comprehensive list of factors available in claims data: opioid
regimen characteristics, pain conditions, physical and mental health conditions, concomitant
medications (benzodiazepine, stimulants, non-opioid analgesics, and polypharmacy), patient
characteristics, and insurance type. Key Results: In our sample, transition to incident COT was
1.3% and pain-specific diagnoses were rare (31.7%). The four leading predictors of COT were
opioid duration-of-action [AOR= 12.28; 95%CI= 8.06-18.72], parent opioid [tramadol vs.

11

codeine, [AOR= 7.26; 95%CI= 5.20-10.13], the presence of conditions highly likely to cause
chronic pain [AOR= 5.47; 95%CI= 3.89-7.68] and drug use disorders [AOR= 4.02; 95%CI=
2.53-6.40]. Conclusions: Initial opioid regimen characteristics are powerful predictors of COT.
Predictive algorithms developed from readily available claims data can be used to develop realtime predictions on future risk of transition to COT.
2.2

Introduction
Chronic non-cancer pain (CNCP) is prevalent among US adults, has costs exceeding half

a billion dollars annually, and can be especially burdensome for working-age adults due to lost
productivity and negative impacts on quality of life.1-6 Many patients suffering from CNCP still
receive opioid therapy, despite lack of robust evidence on the efficacy and effectiveness of
opioids relieving CNCP,7,8 and currently-available effective non-opioid treatments.9 In 2012,
prescriptions for opioids peaked at 259 million prescriptions.7,30
Patients who receive short-term opioid therapy may be at high risk of becoming users of
chronic opioid therapy (COT), defined as use of opioid over 90 days.7,18 COT places patients at
risk of exacerbating current conditions, developing new chronic physical and mental health
conditions, and opioid-related adverse effects such as overdose, abuse, and death.7,19-22 An
estimated 1 in 550 patients with CNCP die from an opioid overdose and the rate of death
increases to 1 in 32 patients, who were prescribed very high daily doses.71 These findings
suggest that opioid regimen characteristics play a crucial role in escalating the risk of COT and
its associated adverse consequences.
However, factors affecting how working-age adults with CNCP transition into COT are
not well understood.7,35 It is important to examine COT among working-age adults because they
may suffer from unique, negative consequences such as missed worked days, loss of
12

employment, and decreased productivity19-24 in addition to the complications related to opioids
such as high economic burden through increased emergency room, inpatient, and other
healthcare utilization.19-24 Given these potentially serious consequences, it is important to
determine the predictors of transitioning from acute to COT among working age adults.25
Identifying working-aged adults who are at high risk for transitioning to COT and determining
the factors which place them at risk for the transition can augment clinicians’ knowledge to aid
with prescribing decisions, initial opioid regimen selection, or monitoring,43,44 as well as to help
inform early risk mitigation efforts, which have shown some efficacy at preventing overdose and
death.7,45,46
Researchers have assessed the transition from acute to COT among Veterans, among
patients using a single healthcare system, or among low-income individuals using Medicaid
claims.18,72,73 Other studies have used predictive models to identify patients who were diagnosed
with incident substance use disorders or opioid abuse. 74,75 To date, no study has analyzed the
transition to incident COT in working-aged adults using nation-wide data. Therefore, the
objective of this study was to identify predictors of transition to incident COT among workingage adults using data from a nationally representative sample of commercially-insured adults in
the US. With this information, clinicians and insurers can personalize treatment options
including non-opioid regimens for adults at high risk for transition to COT; changes to treatment
guidelines based on these predictors can be assessed by researchers, policy makers, and
government payers. We used robust predictive modeling techniques to identify leading predictors
of incident COT using readily available information in claims databases; such modeling can be
applied to real-time data customized to specific regions, providers, or insurers.27,28
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2.3

Methods

Data
The data were derived from adjudicated claims (inpatient, outpatient, emergency room,
and prescription) database of commercial enrollees (approximately 150 million enrollees) which
covered ten years from 2006 to 2015. The researchers received data on 10% random sample of
commercial enrollees released under licensing from the QuintilesIMS information services
(QuintilesIMS RWD Adjudicated Claims - US). The full data from which the 10% was sampled
covers 90% of hospitals, 80% of doctors, and 85% of large companies in the US. This data only
includes health plans who submit data for all of their members and the data are considered
nationally representative for the US commercial-insured population.76,77
Study Design
A retrospective cohort design, with baseline and follow-up periods was used. A patient’s
first prescription for an opioid during the period between January 2007 and May 2015 was
defined as the index date; this index date was used to create baseline (12 months before index
date) and follow-up (120 days after index date) periods. To ensure that we captured individuals
who were opioid-free in the baseline, we used the first prescription date between January 2007
and May 2015. The National Drug Codes (NDCs) for opioids were extracted from the National
Library of Medicine’s (NLM) RxNav (https://mor.nlm.nih.gov/RxNav/) and RxMix
(https://mor.nlm.nih.gov/RxMix/).78 These conversions allowed for categorizing opioids more
granularly (e.g. by parent opioid and duration of action).
Study Sample
The study sample (N = 491,422) consisted of adults, aged 28-63 years at index date,
without cancer, and who were continuously enrolled in a primary, commercial insurance plan
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during the entire observation period (baseline and follow-up periods). Continuous enrollment in
both pharmacy benefits and medical benefits was required. We excluded individuals who had
more than one opioid prescription on the index date because we were unable to evaluate initial
opioid regimen characteristics for these individuals (N=10,594). We excluded few individuals
(N = 23) because of missing of data on region (Figure 2.1).
Measures
Dependent variable
Transition to incident chronic opioid therapy (COT): An enrollee was classified as
having incident COT if he/she had at least 90-day supply of opioids during the follow-up period
(i.e. 120 days after index date).
Independent variables
Opioid regimen characteristics included duration of action (long-acting and immediate
release), standardized dose, and parent opioid. These were assessed using the first opioid
prescription. Parent opioid was grouped into five categories: 1) codeine; 2) hydrocodone; 3)
oxycodone; 4) tramadol; and 5) other opioids. As the data use agreement with QuintilesIMS
specified that opioids manufactured by a single manufacturer could not be isolated, we combined
all the single manufacturer drugs and other opioids into one category. Methadone can be used to
treat opioid use disorder or pain, so it was not included as an eligible opioid for the sample.
Standardized dose was calculated in milligrams of morphine equivalents (mgME) using the
opioid morphine equivalent conversion factors approved by the Centers for Medicare and
Medicaid Services (CMS).79
Enrollment characteristics of patients were: insurance plan type (Health Maintenance
Organization, Preferred Provider Organization, or other) and primary insured relationship (self,
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spouse, other, and unknown). Patient demographics included age, sex, and region (East,
Midwest, South, and West).
Clinical factors were presence or absence of diagnoses for: painful conditions, mental
illnesses,80 and a set of chronic conditions adapted from Department of Health and Human
Services (DHHS) priority conditions for research, program, and policy.81 Painful conditions were
also categorized as: 1) conditions highly likely for chronic pain;82 2) likely for chronic pain;82
and 3) acute pain.83 Arthritis was separated because it was a painful condition as well as a DHHS
priority condition, so that it would not be double counted. The International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes were used to assess each of
these conditions. The ICD-9-CM codes did not overlap between lists. Drug use disorders
included ICD-9-CM codes for drug dependence (304), drug abuse (305.2-305.9), and druginduced mental disorders (292).
Generic Product Identifier (GPI) codes, a hierarchical classification system that identifies
drugs from their primary therapeutic use to package size in 2-digit increments, were used to
assess medication-related characteristics. Medication-related characteristics included
concomitant use of benzodiazepines (GPI-4 = 57.10), stimulants (GPI-4 = 61.10 or 61.40), or
non-opioid analgesics (GPI-2 = 66 or 64). Pharmacotherapy burden was estimated with
polypharmacy defined as five or more medication classes.84 Concomitant medications were
measured during the last four months of the baseline period.
Statistical Analyses: Predictive Modeling
Both standard parametric (logistic regressions) and non-parametric methods based on
decision tree were used for prediction. Random forest, a decision tree method is often used for
predictive accuracy.43 In Random forest, collection of decision trees are built and averaged by
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bootstrapping of samples and variables.43 The two methods were compared using receiver
Operator Characteristic (ROC) curves. Predictive modeling differs from the standard regression
approaches in many ways. While standard regressions focus on the average relationship between
transition to COT and explanatory variables, predictive modeling can be used to target the
patients at highest risk for transitioning to COT like has been done to help develop interventions
for patients with diabetes.85
Standard regressions are typically conducted in a given sample, while predictive models
use bootstrap samples of observations (bagging) and a sample of variables (attribute bagging)
and testing the estimated model in a hold-out or test sample.43,86 To accomplish this, we
randomly split the eligible sample into three subsamples (60% training, 20% validation, and 20%
testing). After a final model was identified using the training and validation subsamples, the
predictive model was tested on the hold-out sample to assess performance and potential overfitting. To increase the utility of a predictive model in a clinical setting, we used an abbreviated
set of factors that could be easily assessed during a patient visit (Model 1). Predictive modeling
was performed in R (R Development Core Team, Vienna, Austria). For comparison with
published literature, we present adjusted odds ratios (AOR) and 95% Confidence intervals (CI)
by conducting a logistic regression of the final models in the test subsample.
2.4

Results

Sample description
Overall, in this sample of working-aged adults, the transition from first opioid
prescription to incident COT was 1.3% (n=6,556) (Table 2.1). Hydrocodone was the most
frequently prescribed first opioid (61.0%) followed by oxycodone (19.3%), tramadol (9.9%), and
codeine (9.1%). The majority of the eligible sample was female (52.5%), 45 years of age or older
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(56.7%), and on PPO plans (73.9%). The majority of these patients (68.3%) did not have an
indication in their medical claims for acute pain, arthritis, or conditions highly likely or likely for
chronic pain.
Selected key sample characteristics by transition to COT are presented in Table 2.1.
Opioid regimen characteristics (parent opioid, duration of action, and standardized dose) were all
associated with the transition from first opioid prescription to incident COT. A higher
percentage of patients with first opioid prescriptions for long-acting formulations (37.0% vs.
1.3% immediate release), tramadol (4.2% vs 0.5% codeine), very high standardized doses (5.1%
vs 1.5% lower), patients who had conditions most likely to cause chronic pain (17.2% vs. 1.3%
without), and patients with drug use disorders (12.4% vs. 1.3% without) transitioned to COT.
Predictive modeling
In training/validation subsamples, the following variables were the leading predictors
after adjusting for sex, age, presence of painful conditions, and readily available and modifiable
opioid regimen factors (opioid duration of action, parent opioid, and standardized dose).
Variables of importance (absolute value of the beta-coefficient) in descending order as they
related to transition to incident COT included: duration of action, likely chronic pain condition,
parent opioid, highly likely pain condition, and drug use disorder diagnoses. In the hold-out
sample, the same predictors were found to be important although the order changed somewhat.
For example, drug use disorders became the fourth leading predictor in the hold-out sample as
opposed to second leading predictor in the training/validation samples. In the fully adjusted
model, the leading predictors remained the same in both training/validation and test samples.
Again, the order of importance varied somewhat with the drug use disorders variable becoming
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the fifth leading predicator in the hold-out sample as opposed to third leading predictor in the
training/validation samples.
The similarity between the two models was also confirmed by the prediction accuracy of
Model 1 and fully-adjusted model (Figure 2.2). The Areas under the Curve (AUC) were similar
for Model 1 (AUC = 0.78) and the fully-adjusted model (AUC = 0.78) using the hold-out
sample. The AUC of decision-tree based models using random forest on the variables from
Model 1 and the fully-adjusted model were 0.54 and 0.64 in training/validation subsample,
respectively.
As mentioned earlier, for ease of comparisons with published literature, Table 2.2
summarizes the findings in the form of AOR and 95% CIs from a logistic regression of the test
sample. As can be seen from the table, fully-adjusting the model did not make large changes to
the AORs. For example duration of action (long acting vs. immediate release, AOR = 12.43,
95% CI = 8.13-18.83) in model 1 was similar in the fully-adjusted model (AOR = 12.28, 95% CI
= 8.06-18.72).
2.5

Discussion
This is the first study to identify incident COT in a sample of working-aged adults, who

were initiated on opioid therapy. This is an important group to focus on because of the impact on
productivity and their increased likelihood to receive opioid therapy when they experience
pain.25 In absolute terms, nearly half a million working-age adults in this sample were initiated
on opioid therapy over the observation period. For example, in 2014 there were 1,799,106
million prescriptions for opioid drugs in our 10% sample. As a rate, we found that 13 out of 1000
patients with initial prescription of opioids transitioned to COT.
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Another important finding was differences between states in the US. The rates of patients
who transitioned to incident COT was higher in Ohio, West Virginia, Kentucky, Mississippi, and
Nevada than other states. These states are often in the media reporting opioid overdoses and
problems; however, more study could be done to look for specific state issues, including
monitoring of prescribers, education of public and prescribers, and availability of nonpharmacotherapy treatments for CNCP.
Our study findings demonstrated that a smaller set of more easily assessed factors at
initiation (duration of action, standardized dose, parent opioid, age, sex) can be used to gauge the
risk of transition to COT. Our predictive models identified four leading predictors that increased
the risk of transition to COT by at least four times. These were: duration of action, type of
parent opioids, drug use disorders, and painful conditions.
In our sample of working age adults, the highest likelihood of transition to COT was
among adults who were prescribed extended release opioids as opposed to immediate release.
These findings have implications for clinical practice. First, prescribers can use these factors to
determine the potential for an individual patient to transition to incident COT at the time of their
first prescription for opioids. With the knowledge of this potential risk, regimens could then be
altered or monitoring increased. Pharmacists can also use these factors and provide counseling
about goals of pain management or the risks of COT, to a subset of patients who are at high risk
of transitioning to COT. Future intervention efforts can effectively target these factors to change
prescribing practices of opioids.7 For example, immediate release, low-dose codeine can be firstline option. However, other opioids may be needed, since codeine is a weak opioid and there are
pharmacogenomic differences (e.g. poor metabolizers will have a reduced response) that need to
be considered for codeine use.87 In addition, future studies using qualitative and quantitative
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analyses could assess prescriber logic in how they chose to prescribe extended release versus
immediate release. What clinical characteristics or patient preference issues were considered in
making these choices? There may be underlying issues that are uncovered.
In our sample, only a third of working-age adults, with first prescription of opioids had
any diagnosis of painful conditions. While it is plausible that ICD-9-CM codes may under-report
painful conditions, without the full documentation of indications for opioid use, it is difficult to
assess appropriateness of initial opioid prescription. This has implications for prescription
monitoring programs, state-based insurers, health care systems, local hospitals, and outpatient
practices, as well as emphasizing the need for documentation requirements or recommendations.
Strengths of this study include the availability of a nationally-representative sample of the
US commercially-insured population, following individuals across multiple providers and
settings, use of statistical and machine learning predictive methods, and availability of dates so
that we could identify first, index opioid prescription. Also, this study assessed incident COT,
which other studies have not distinguished from prevalent use of chronic or long-term opioid
therapy. By using the NLM programs RxMix and RxNav to identify clinical drug components,
the duration of action and parent opioid for each prescription could be identified, which allowed
for more granular assessment of the opioid regimen using claims data. Finally, the data spanned
many unique insurers and plan types, which allowed for the tracking of patients through time and
to determine an opioid-free period of 12 months.
The study also has some potential limitations. First, prescription claims do not have
information on variables such as pain, socio-economic status, social capital, medication beliefs,
and response to pain treatment, which may affect transition to COT. Also, claims data allow for
the identification of prescription medication, but not actual use of these medications. There are
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limitations of the predictive modeling results as well. The models were assessed in a unique
subsample (testing data) of the overall sample. However, the validity of the model and its
predicted probabilities will be more generalizable if applied to a different sample of patients,
potentially from other commercial healthcare plans. The importance of factors could change, and
even be improved if other types of information were added to the dataset (e.g. social
determinants of health, medication use behaviors, prescriber characteristics).
2.6

Conclusion
Our study findings suggest that an individual’s transition to COT can be predicted by

information readily available in a clinical setting such as the initial opioid regimen
characteristics, past history of drug use disorder, and painful conditions. Our study highlighted
that predictive models can be used to aid clinician’s decision making; develop real-time
predictions about future risk of transition to COT; influence policy, prescriber education, and
prescription monitoring programs; and can applied to other patient populations. Future research
may include other factors, including medication taking behaviors, not measured in our study and
improve prediction accuracy.
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Table 2.1. Sample description for patients with incident opioid use by transition to chronic opioid therapy (COT)
after initial opioid prescription, using QuintilesIMS Real-World Data Adjudicated Claims - US, 2006-2015
Total (n)
Transition to Transition to
Χ2
p-value
COT (n)
COT (%)
491,442
6,556
1.3
All
Opioid Regimen Characteristics
Duration of action of initial opioid prescription
Long acting
819
303
Immediate release
Parent opioid of initial opioid prescription
Codeine
Hydrocodone

490,623

6,253

44,588

201

0.5

3,023

1.0

94,822

1,039

1.1

Tramadol

48,450

2,039

4.2

3,574

254

7.1

Standardized dose* of initial opioid prescription
Lower (0-49)
370,726

5,520

1.5

106,544

776

0.7

11,399

118

1.0

2,773
Pain Conditions

142

5.1

1,508

259

17.2

489,934

6,297

1.3

High (100-149)
Very high (≥150)
Highly likely chronic pain condition
Yes
No
Likely chronic pain condition
Yes
No
Acute pain condition
Yes
No

4494.2

<0.001

674.4

<0.001

2883.8

<0.001

2029.9

<0.001

26.5

<0.001

1241.5

<0.001

462.5

<0.001

1401.7

<0.001

612.0

<0.001

1.3

300,008

Moderate (50-99)

<0.001

37.0

Oxycodone
All other opioids

7926.7

144,644

3,581

2.5

346,798

2,975

0.9

4,247
487,195

95
6,461

2.2
1.3

Yes

30,811

1,098

3.6

No

460,631

5,458

1.2

Arthritis

Physical and Mental Health Conditions
Mental illness
Yes
No
Any drug use disorder
Yes

58,356

1,338

2.3

433,086

5,218

1.2

1,513

187

12.4

489,929

6,369

1.3

Concomitant Medications
Benzodiazepine use within four months preceding opioid prescription
Yes
39,048
1,059

2.7

No

No

452,394

Continued
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5,497

1.2

Table 2.1. Sample description for patients with incident opioid use by transition to chronic opioid therapy (COT)
after initial opioid prescription, using QuintilesIMS Real-World Data Adjudicated Claims - US, 2006-2015
Total (n)
Transition to Transition to
Χ2
p-value
COT (n)
COT (%)
105.2
<0.001
Stimulant use within four months preceding opioid prescription
Yes
No

7,642

204

2.7

483,800

6,352

1.3

Non-opioid analgesic use within four months preceding opioid prescription
Yes
120,486
1,983
No
Polypharmacy (≥5 drug groups)
Yes
No

370,956

4,573

117.9

<0.001

528.9

<0.001

1.6
1.2

109,724

2,234

2.0

381,718

4,322

1.1

Patient Characteristics
94.0

Sex
Male

233,393

3,503

1.5

Female

258,049

3,053

1.2

28-34 years

81,462

602

0.7

35-44 years

130,917

1,345

1.0

45-54 years

156,191

2,332

1.5

55-63 years

122,872

2,277

1.9

Age

Region
East

94,910

1,075

1.1

Midwest

156,117

2,090

1.3

South

194,746

2,862

1.5

West

45,669

529

1.2

<0.001

594.2

<0.001

67.2

<0.001

24.0

<0.001

Insurance Characteristic
Insurance plan type
HMO
PPO
Other†

63,181

798

1.3

363,414

5,010

1.4

64,847

748

1.2

Note: This sample includes patients from QuintilesIMS RWD Adjudicated Claims – US, which were identified
between 2007-2015 and had enrollment between 2006-2015. These patients were between 28-63 years old,
without cancer, had complete demographic information available, and had only one opioid prescription on the
index date. Due to data use requirements, some categories were collapsed. These include insurance plan type and
other opioids.
*: Doses of opioids were converted to a standardized dose (milligrams of morphine equivalent) using the Centers
for Medicare and Medicaid Services conversion table.
†: Other insurance types included fee-for-service, health savings account, and indemnity.
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Table 2.2. Select leading predictors from a logistic regression with adjusted odds ratio (AOR) and 95% confidence
interval (95%CI) for patients with incident opioid use by transition to chronic opioid therapy (COT) after first opioid
prescription, using QuintilesIMS Real-World Data Adjudicated Claims - US, 2006-2015
Model 1 in
Fully adjusted Model 2
Test subsample
in Test Subsample
AOR 95% CI
Sig
AOR 95% CI
Sig
Long-acting vs. Immediate release

12.43

[8.13,18.83]

***

12.28

[8.06,18.72]

***

Tramadol vs. Codeine
Highly likely chronic pain vs. None

7.59
5.91

[5.53,10.74]
[4.18,8.20]

***
***

7.26
5.47

[5.20,10.13]
[3.89,7.68]

***
***

All other opioids vs. Codeine

5.71

[3.38,9.59]

***

5.64

[3.34,9.53]

***

Drug use disorder diagnosis vs. None
Oxycodone vs. Codeine

4.96
2.70

[3.13,7.58]
[1.92,3.90]

***
***

4.02
2.67

[2.53,6.40]
[1.87,3.81]

***
***

Likely chronic pain vs. None
Hydrocodone vs. Codeine

2.08
2.04

[1.84,2.34]
[1.49,2.87]

***
***

2.02
1.97

[1.79,2.28]
[1.42,2.73]

***
***

Benzodiazepine prescription vs. None
Arthritis vs. None

1.99
1.92

[1.69,2.33]
[1.63,2.25]

***
***

1.82
1.86

[1.54,2.16]
[1.58,2.20]

***
***

Male vs. Female

1.43

[1.27,1.60]

***

1.46

[1.30,1.65]

***

Very high vs. Low dose†
Age (continuous)

1.27
1.02

[0.73,2.08]
[1.02,1.03]

***

1.24
1.02

[0.74,2.08]
[1.01,1.03]

***

High vs. Low dose†
Moderate vs. Low dose†

0.71
0.45

[0.47,1.05]
[0.37,0.55]

***

0.68
0.45

[0.45,1.02]
[0.37,0.54]

***

Note: This sample includes patients from QuintilesIMS RWD Adjudicated Claims – US, which were identified
between 2007 and 2015 and had enrollment between 2006 and 2015. These patients were between 28-63 years old,
without cancer, had complete demographic information available, and had only one opioid prescription on the index
date. Due to data use requirements, some categories were collapsed. These include insurance plan type and other
opioids. Other variables included in the fully adjusted model can be seen in the supplemental materials.
†: Doses of opioids were converted to a standardized dose (milligrams of morphine equivalent) using the Centers for
Medicare and Medicaid Services conversion table.
Significance: 0 < p < 0.001 = ***, 0.001 ≤ p 0.01 = **, 0.01 ≤ p < 0.05 = *
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Figure 2.1. Application of inclusion and exclusion criteria to the sample of patients with incident opioid
prescriptions from QuintilesIMS Real-World Data Adjudicated Claims – US, which were identified between 2007
and 2015.
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Figure 2.2: Receiver operator characteristic (ROC) curves for Model 1 (orange, AUC = 0.776) and Fully Adjusted
Model 2 (purple, AUC = 0.782) using the test subsample
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CHAPTER 3
3

Increased healthcare utilization and expenditures associated with transition to chronic
opioid therapy

3.1

Abstract

Objective: To assess the association between transitioning from incident opioid use to chronic
opioid therapy (COT), on the trajectories of health utilization and expenditures Data sources:
Commercial claims database (10% sample of QuintilesIMS Real-World Data Adjudicated
Claims – US) from 2006-2015 Study design: Longitudinal, retrospective cohort design, using
seven, 120-day time periods covering pre-index (t1- t3), index (t4), and post-index (t5- t7) with
data from adults, aged 28-63 years, without cancer, and who were continuously-enrolled in a
primary, commercial insurance plan (n= 20,201). Multivariable analyses were performed on
utilization [population-average (PA) logistic regression], expenditures (PA generalized
estimating equations), and expenditure estimates (counterfactual prediction). Data
collection/extraction methods: Fully-adjudicated pharmacy, hospital, and medical claims sourced
from commercial payers Principal findings: Patients who transitioned to COT were more likely
to use inpatient services [AOR=1.11, 95%CI(1.01,1.21)] compared to those who did not
transition. While expenditures peaked during the transition period (t4) for all users, differences in
unadjusted average, 120-day expenditures between COT and no COT users were highest in t4 for
total ($4,607) and inpatient expenditures ($2,453). COT users had significantly higher total
(=0.183, p<0.01) and inpatient expenditures (=0.448, p<0.001). Conclusions: The period after
incident opioid prescription, but before COT, is an important time for intervention for payers.
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3.2

Introduction
Nearly half of Americans have experienced pain in the past year, and approximately 100

million suffer from chronic pain 1,3. The vast majority of these patients suffer from pain not
related to cancer, also known as chronic non-cancer pain (CNCP), and are working age 1,2,4-6.
CNCP can be managed using many different therapy regimens including pharmacologic options
(non-opioid pharmacotherapy and opioid therapy) and non-pharmacologic options, which have
been shown effective (e.g. electrical stimulation, physical therapy, psychological interventions,
or exercise) 7,9,29. Opioids have been recommended to be used only after considering a nonopioid analgesic regimen. Nearly one in five patients who presented to their healthcare provider
with a painful condition in 2010 were prescribed an opioid even though the effectiveness of
opioids in relieving non-cancer pain has not been proven 31.
In addition to the lack of evidence for opioids to treat CNCP, they also lead to adverse
health consequences including cardiovascular risk, endocrine disorders, opioid use disorder, and
death 7. Multiple studies have also documented increased healthcare utilization and expenditures
to patients and payers due to adverse health effects of opioids 3-5,23. Patients who were prescribed
opioids had higher emergency department, inpatient, and outpatient visits, as well as increased
analgesic use, out-of-pocket spending, and third-party spending compared to patients not
prescribed opioid medications 19,23,48,49. For example, prescription opioids accounted for nearly
16,000 age-adjusted overdose deaths, in 2015 88. This can lead to high economic burden through
increased emergency room, inpatient, and other healthcare utilization and healthcare
expenditures 19-24. Using older data from 2011, it has been reported that 1,000 people were
treated in emergency rooms daily for misuse of prescription opioids 22. The number of annual
emergency department visits due to opioids doubled from 2004 to 2011 19. From 1993 to 2012,
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the rate of hospital inpatient stays related to opioid overuse, per 100,000 population, increased
from 116.7 to 295.6, a cumulative increase of 153%.21
Patients who receive initial opioid therapy, even for only a few days, are at risk of
transitioning to chronic opioid therapy (COT), defined as 90 days of use 7,18. For example our
preliminary analysis has shown that initial opioid prescription characteristics (parent opioid,
duration of action, and standardized dose) are the leading predictors of transitioning to COT 89.
Another, prospective, study found that expectations about opioid use in the future predicted COT
18

. Both patients and payers can bare the economic consequences of COT, which results from

exacerbation of current medical conditions, development of new physical and mental health
conditions, and opioid-related adverse effects including drug use disorder, and opioid overdose
7,19-22

. Every year, an estimated $78 billion is spent on these adverse consequences of opioids 24.
Although researchers have estimated the economic burden of developing an opioid use

disorder in patients on opioid therapy 24,49,90; studies that systematically examined the effect of
the transition to COT has on healthcare utilization and expenditures are sparse 10,20. Such studies
are important because they assess a transition state generally earlier in patient’s continuum of
care 42, and this earlier period has been identified by the Centers for Disease Control and
Prevention (CDC) as a time to take action 7. To date, only one study analyzed the association
between long-term opioid therapy and other opioid therapy on healthcare utilization and
expenditures 20. Using data from commercial health plans, the study reported that healthcare
expenditures were higher among long-term opioid users compared to other opioid users 20. This
study had some limitations such as use of non-standard definition of long-term opioid therapy,
and unequal follow-up time periods between short- and long-term opioid users. The definition
for chronic opioid users (>182 days) was different from the commonly-used Agency for
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Healthcare Research and Quality (AHRQ) and CDC definition of ≥90 days (3 months) 7,8.
Furthermore, the study was not restricted to working-age adults who may have different
transition rates and factors affecting those rates. Our study addresses the limitations of the prior
literature and analyzes the impact of transitions from initiation of opioids to COT on economic
outcomes in a nationally-representative sample of working age adults using definitions
concordant with definitions used by CDC, AHRQ, and current literature 7,8,50,51.
Focusing on working age adults in the age group 18-64 years is important because this
group may have higher risk of transition to COT transition 91 and their healthcare utilization
patterns may be unique compared to the elderly 92. Therefore, the objective of our study was to
assess the association between transitioning from incident opioid use to incident chronic opioid
therapy (COT), on the trajectories of health utilization and expenditures using a nationallyrepresentative sample of commercially-insured working-aged adults in the United States (US).
3.3

Methods

Data Source
The data were derived from a 10% random sample of commercial enrollees released
under licensing from the QuintilesIMS (QuintilesIMS RWD Adjudicated Claims - US).
Study design
A retrospective cohort design with longitudinal data for seven, 120-day, time periods
covering pre-index (t1, t2, and t3), index (t4), and post-index (t5, t6, and t7) was used. The patient
cohort consisted of working aged adults, without cancer and who were initiated on opioids
between January 2007 and May 2014. The first observed prescription for an opioid represented
the index date. The pre-index periods were identified before the index date, the index period was
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identified as 120 days after the index opioid prescription, and the post-index periods were
identified after the end of the index period.
Study sample
The sample was restricted to adults, aged 28-63 years at index date, without cancer, and
who were continuously enrolled in a primary, commercial insurance plan during the entire
observation period. The patient age of 63 was chosen so that full index and post-index periods
would still result in a patient less than 65 years (the age in which they are eligible for Medicare).
Cancer was identified using the International Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) codes. Patients with at least one claim with any cancer code (except
for non-melanoma skin cancer) in any of the 12 diagnosis code fields available in the claims data
were considered as having cancer 81. Continuous enrollment in both pharmacy benefits and
medical benefits was required. We excluded individuals who had more than one opioid
prescription on the index date because we were unable to evaluate initial opioid regimen
characteristics for these individuals. After applying the exclusion criteria, we observed 3,776
adults in the COT group. A 5% random sample, approximately 5 controls per case, of patients
without COT was selected to represent the No COT group (N = 16,425) (See Appendix 1).
Measures
Dependent variables: Healthcare utilization and expenditures
All healthcare utilization and expenditures were repeatedly measured for each time
period. Utilization consisted of emergency department (ED) and inpatient. ED use was
identified using previously published algorithm based on place of service, procedure codes, and
revenue center codes 93. Inpatient use was identified based on the claim having a non-missing
value for confinement number (a unique number with the claims, indicating hospitalization).
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Inpatient claims with the same confinement number were aggregated to get the admission and
discharge dates. We measured utilization by any use of ED or inpatient, defined as having at
least one claim for these services during the 120-day time period.
Expenditures were distinguished by type of service [ED, inpatient, physician, and other
(e.g. surgical services, diagnostics, and laboratory tests)]. Total expenditures (without
prescription drugs) were the sum of ED, inpatient, physician, and other. Expenditures were
calculated using the actual amount paid by the insurance plan; they were converted to 2015 US
dollars using the US Bureau of Labor Statistics Consumer Price Index (CPI) for Medical Care
Services 94.
Key independent variable
Transition to incident chronic opioid therapy (COT): Opioids were identified using the
National Drug Codes (NDCs). NDCs for opioids were extracted from the National Library of
Medicine’s (NLM) RxNav (https://mor.nlm.nih.gov/RxNav/) and RxMix
(https://mor.nlm.nih.gov/RxMix/) 78. A patient was classified as having incident COT in he/she
had at least 90-day supply of opioids during the 120-day index period.
Other independent variables
Time invariant characteristics (patient’s sex, region of residence, and clinical factors)
were measured during the 12 months before index date. Age was calculated as of the index date
for initial opioid prescription. Clinical factors were presence or absence of diagnoses for: painful
conditions 82, mental illnesses 80, drug use disorders, and number of other chronic conditions
adapted from Department of Health and Human Services (DHHS) priority conditions for
research, program, and policy.81 Painful conditions were categorized as conditions highly likely
for chronic pain or likely for chronic pain 82. Drug use disorders included ICD-9-CM codes for
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drug dependence (304), drug abuse (305.2-305.9), and drug-induced mental disorders (292). The
ICD-9-CM codes were used to assess each of these conditions and did not overlap between lists.
The clinical complexity of a patient was also measured during each time period by the
number of unique medication classes. We also assessed concomitant medication use, specifically
benzodiazepines and prescription non-opioid analgesics, at each time period. Generic Product
Identifier (GPI) codes were used to identify number of unique medication classes, as well as
benzodiazepines (GPI-4 = 57.10) and prescription non-opioid analgesics (GPI-2 = 66 or 64).
Additional independent variables included continuous time (range 0-6 corresponding to t1-t7) and
an indicator variable for the index period (t4) to capture the differential rates of healthcare
utilization and expenditures during this period.
Statistical Analyses
As we repeatedly measured healthcare utilization, expenditures, unique medication
classes, and concomitant medication use every 120-days, each individual had seven observations.
These seven observations were not independent and applying standard regression techniques can
lead to misleading results. Therefore, the unadjusted and adjusted relationships between COT
and economic outcomes were analyzed with a repeated measures design. Healthcare
expenditures are unique (e.g. non-normal distribution, high number of enrollees with zerovalues, and non-negative measurement of the outcomes of interest). Therefore, we used the
generalized linear mixed models (GLMM), which can accommodate both linear and non-linear
outcome variables. Mixed-effects regressions can model both within and between subject
variations. However, one needs to distinguish between population-averaged (PA) and subjectspecific (SS) models for binary outcomes 95 as well as continuous outcomes within GLMM. We
used PA models with generalized estimating equations (GEE) to analyze the relationship
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between COT and ED use, inpatient use, and expenditures. For this study, the population
average (PA) approach was used because the objective was to estimate the average treatment
effects between the COT and non-COT group. In multivariable GEE models, we adjusted for
time as a continuous variable (range 0-6), number of other chronic conditions, sex, age, region,
history of drug use disorder, painful conditions, benzodiazepine use, non-opioid analgesic use,
and number of unique medication classes.
Three models were developed to analyze the relationship between COT indicator and the
dependent variables. The first model (Model 1) is only adjusted for continuous time, and the
index period (t4). Model 2 additionally adjusted for the number of chronic conditions, while
Model 3 is the fully adjusted model and includes additional adjustments for sex, age, region,
history of drug use disorder, painful conditions, benzodiazepine use, non-opioid analgesic use,
and number of unique medication classes.
We calculated the differences in average expenditures between COT and no COT groups
with a counterfactual prediction technique. This was done because exponentiating expenditures
for the COT and no COT groups to derive absolute differences in dollar amount assumes a
reference case scenario. Rather than simply comparing the expenditures between the groups, by
holding other variables constant, we used the counterfactual prediction technique. Under this
technique, expenditures for counterfactual scenarios (e.g. assuming all patients with and without
COT while keeping their other characteristics as given) were calculated and differences in
average expenditures were estimated 96-99. Confidence intervals for these estimates were obtained
using 1000 bootstrap replications using the percentile method. Datasets for these analyses were
created using SAS (version 9.4) and analyses were performed using STATA (version 14).
Inverse Probability of Treatment Weighting
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Patients receiving COT or non-COT regimens may systematically differ in observed
characteristics (e.g. painful conditions). Therefore, to control for observed selection bias between
patients transitioning to COT and those not transitioning to COT, we used inverse probability of
treatment weighting (IPTW) 100. Patient sex, age categories, region, and pain conditions were
used in a logistic regression on COT use to derive IPTW and were used as patient weights in
designated analyses.
3.4

Results

Description of the study sample by COT
The sample characteristics (sex, age, region, and pain conditions) were significantly
different between COT and non-COT groups (all p<0.001). After adjustment for IPTW, there
were no longer any significant differences. The sample comparison before and after IPTW is
displayed in Supplemental Table 7.2.1.
Healthcare utilization
ED utilization differed significantly across time periods (p<0.001) between patients that
transitioned to COT compared to those who did not, in the unadjusted analyses (Table 3.1). For
patients with COT, ED use increased from 6.0% (t1) to 15.5% (t4); similarly, for patients without
COT, ED use increased from 4.3% (t1) to 15.3% (t4). ED use remained higher in the COT group
as compared to the no COT group in the follow up time periods (t5, t6, and t7). As displayed in
Table 3.2, using adjusted Models 1 and 2, patients who transitioned to COT were more likely to
have ED utilization [AORs=1.33,95%CI(1.25,1.42) and 1.26(1.17,1.34), respectively] compared
to those who did not transition to COT. However, in Model 3, the patients who transitioned to
COT were less likely to have ED use [AOR=0.92, 95%CI(0.86,0.99)].
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Similarly, inpatient use increased from 1.5% (t1) to 10.9% (t4) in patients with COT; for
patients without COT, inpatient use increased from 1.1% (t1) to 5.4% (t4) (Table 3.1). Inpatient
use remained higher in the COT group as compared to the no COT group in the follow-up time
periods (t5, t6, and t7). Patients who transitioned to COT were more likely to have inpatient use in
all three models [AOR= 1.78 95%CI(1.63,1.94), 1.45 (1.33,1.58), and 1.11 (1.01,1.21), for
Models 1, 2, and 3, respectively] (Table 3.2). Finally, both ED and inpatient use were more
likely to occur during the index period (t4) compared to all other periods (p<0.001) (Table 3.2).
Healthcare expenditures
Average expenditures over time and by COT use are summarized in Table 3.3 and
differences in unadjusted mean expenditures over time, among COT and non-COT users by type
of service, are graphed in Supplemental Figure 7.2.1. Patients who transitioned to COT had
higher total expenditures at every time point, and the difference in mean expenditures between
these groups varied significantly as time progressed. In t1, the patients that transitioned to COT
only had $511 higher total expenditures, but that increased to $4,607 in t4. The differences in
average expenditures peaked during the index period (t4) and remained higher than baseline
through the entire follow-up period, driven mostly by inpatient expenditures.
Patients who transitioned to COT had significantly higher total (p=0.002) and inpatient
(p<0.001) expenditures in the fully adjusted analyses (Table 3.4). Also, the index period (time
period 4) was associated with higher expenditures for every type, compared to baseline. In the
fully adjusted model, we observed a difference of $579 in t4 between COT and non-COT users
using the counterfactual prediction technique (Figure 3.1).
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3.5

Discussion
Generally, healthcare utilization and expenditures were higher during the index period (t4)

compared to all other time periods for all opioid users (regardless of transition to COT). The only
exception to this was for non-COT users, inpatient expenditures were higher in t3. For those with
and without transition to COT, expenditures increased by 594% and 698% in the period prior to
the initial prescription of opioids (t1 to t3) suggesting that the periods surrounding the initial
opioid prescription are associated with high utilization and expenditures. However, COT users
had higher rate of increase in expenditures as compared to no COT users.
Most trajectories of healthcare utilization and expenditures (from t1 through t7) were
different between COT and non-COT users. For example, among COT users, healthcare
utilization and expenditures were the highest at the index period (t4), but for those who did not
transition to COT, the peak utilization and expenditures were observed in t3, prior to initial
opioid receipt. Furthermore, for patients who transitioned to COT, the utilization and
expenditures remained higher than baseline. For patients who did not transition to COT,
utilization and expenditures returned to closer to initial pre-opioid levels measured at t1 after
adjusting for other characteristics.
In the fully-adjusted models, transition to COT was associated with higher inpatient
utilization and inpatient expenditures as well as total expenditures (without prescription drugs).
The has implications for payers because inpatient use has been reported to be the primary driver
of total expenditures 20. In our study, the proportion of inpatient expenditures to total
expenditures varied from 50% (t1) to 80% (t3) in COT users.
Any intervention focused on curbing transition to COT has the potential to prevent
inpatient use and can lead to cost savings for the payer(s). Interventions include extensive
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physician and patient education about pain management and opioids, the further interoperability
of state-level prescription drug monitoring programs, and increase options for disposal of unused
opioid medications 101. Future research could use this study as part of the way to assess the cost
effectiveness of the mentioned interventions. In addition to expenditures, reduction in inpatient
utilization has benefits for the patient including improved quality of life and lower out of pocket
costs.
Without adjustments for patient complexity (e.g. number of unique medication classes,
highly likely chronic pain conditions, and likely chronic pain conditions), patients who
transitioned to COT were more likely to use ED as compared to patients who did not. However,
in the fully-adjusted model, ED use was less likely between patients who transitioned to COT
compared to those who did not. While we do not know the reasons for this counter-intuitive
finding, we speculate that ED use may be due to patient complexity requiring pain management,
which may have led to an initial prescription of opioid in the index period (t4). Initial prescription
for opioids may have provided short-term relief decreasing their need for emergency care.
Although not directly comparable, our study findings were similar to the study published
by Kern, et.al. assessing the transition from initial opioid prescription to long-term opioid use 20.
For example, Kern, et.al. reported that for long-term users of opioids, healthcare utilization rates
(e.g. ED, inpatient, and outpatient visits) and costs decreased after the first 6 months of followup, but remained above the baseline levels 20. Kern et.al. also reported that the number of ED
visits per patient-year of follow-up were lower for patients receiving long-term opioid therapy
compared to short-term use (0.44 vs. 0.93).
Strengths and limitations
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Strengths of this study include the use of a nationally-representative sample of the US
commercially-insured population, following individuals across multiple providers and settings.
This longitudinal design with repeated measures of utilization and expenditures for patients with
and without transition to COT allowed for an assessment of baseline utilization and expenditures.
This allowed us to control for baseline profiles in terms of utilization, expenditures, and patient
complexity. The data spanned many unique insurers and plan types, which allowed for the
tracking of patients through time and to determine an opioid-free period of 12 months (t1-3).
Furthermore, we applied robust statistical methods to control for observed selection bias.
This study also has some potential limitations. We only observed prescription claims and
not actual use of medications. The database did not have information on variables such as pain,
socio-economic status, social capital (i.e. social relationships that have benefits to production),
medication beliefs, and response to pain treatment, which may have affected the transition and
associated healthcare utilization and expenditures. Although observed selection bias was
controlled for, we did not control for selection bias due to unobserved characteristics. Thus, all
selection bias may not have been eliminated.
3.6

Conclusion
Transitioning to COT can place a significant economic burden on payers and patients in

terms of healthcare utilization and expenditures. Despite having similar baseline values, patients
making the transition to COT had persistently high levels of utilization and expenditures even
after 12 months following the transition to COT. The period of time after incident opioid
prescription, but before COT, is an important time for intervention for payers and clinicians.
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Table 3.1. Rates of emergency department (ED) and inpatient use by transition to chronic opioid
therapy (COT) after initial opioid prescription
QuintilesIMS Real-World Data Adjudicated Claims Database- US, 2006-2015
Emergency Department Use*
Time

COT (Wt. %)

Inpatient Use *

No COT (Wt. %)

COT (Wt. %)

No COT (Wt. %)

1

6.0

4.3

1.5

1.1

2

5.5

4.1

1.7

0.9

3

11.2

12.4

5.9

9.2

4

15.5

15.3

10.9

5.4

5

11.4

5.3

5.9

1.9

6

10.1

5.7

4.5

2.2

7
9.3
5.2
4.0
1.6
Note: This sample includes patients from QuintilesIMS RWD Adjudicated Claims – US, which were
identified between 2007-2014 and had enrollment between 2006-2015. These patients were between
28-63 years old, without cancer, had complete demographic information available, and had only one
opioid prescription on the index date. Individual weights based on IPTW have been used for this
analysis.
*: Significant differences in ED use and IP use by COT category over time using chi-square tests
Abbreviations: COT- chronic opioid therapy; Wt- weighted
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Table 3.2 Adjusted odds ratio (AOR) and 95 % confidence intervals (95%CI) of selected Variables
From population-average Generalized Estimating Equations
Working-Age Adults with incident Opioid Prescription
QuintilesIMS Real-World Data Adjudicated Claims Database - US, 2006-2015
Emergency Department Use
Inpatient Use
Model 1: Adjusted for COT, Time and Index Period(t4)
Variables

AOR

95% CI

Sig

AOR

95% CI

Sig

COT

1.32

[1.25,1.42]

***

1.78

[1.63,1.94]

***

Time

1.04

[1.03,1.06]

***

1.04

[1.03,1.06]

***

Index Period (Time 4)
2.26 [2.12,2.40]
***
1.62 [1.43,1.83] ***
Model 2: Adjusted for COT, Time Index Period(t4), and Number of other Chronic Conditions
COT

1.25

[1.17,1.34]

***

1.45

[1.33,1.58]

***

Time

1.04

[1.03,1.06]

***

1.05

[1.03,1.07]

***

Index Period (Time 4)
2.27 [2.13,2.41]
***
1.81 [1.62,2.02] ***
Model 3: Adjusted for COT, Time Index Period (t4), and Number of other Chronic Conditions, Sex,
Age, Region, History of Drug Use Disorder, Painful Conditions, Benzodiazepine Use, Non-opioid
Analgesic Use, and Number of Unique Medication Classes.
COT

0.92

[0.86,0.99]

Time

0.99

[0.98,1.00]

*

1.11

[1.01,1.21]

*

0.978

[0.96,0.99]

*

Index Period (Time 4)
1.64 [1.54,1.75]
***
1.13 [1.00,1.29]
Note: This sample includes patients from QuintilesIMS RWD Adjudicated Claims – US, which were identified
between 2007-2014 and had enrollment between 2006-2015. These patients were between 28-63 years old,
without cancer, had complete demographic information available, and had only one opioid prescription on the
index date. Individual weights based on inverse probability of treatment weighting (IPTW) have been used for
this analysis.
Abbreviations: COT- chronic opioid therapy; Wt- weighted; AOR- adjusted odds ratio;
Sig: 0 < p < 0.001 = ***, 0.001 ≤ p 0.01 = **, 0.01 ≤ p < 0.05 = *
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Table 3.3 Average expenditures (2015 US dollars) over time by Type of Service and Chronic Opioid Therapy
(COT) use
Working-age Adults (aged 28 – 63) without Cancer and initiated on Opioid Therapy
QuintilesIMS Real-World Data Adjudicated Claims Database- US, 2006-2015
COT
No COT
Mean
(SD)
Mean
(SD)
Total Expenditures†***
Time
t1
$1,214.29
$5,370.49
$702.98
$3,381.23
t2
$1,533.36
$10,527.42
$718.73
$3,020.19
t3
$4,750.20
$22,883.82
$3,394.63
$13,281.89
t4
$8,086.02
$24,328.52
$3,478.55
$9,558.53
t5
$4,615.81
$16,668.22
$1,480.62
$7,397.14
t6
$3,951.71
$16,045.87
$1,574.25
$8,258.62
t7
$3,382.53
$12,654.83
$1,289.55
$6,838.75
Time
Emergency Department***
t1
$54.05
$329.90
$44.82
$586.10
t2
$73.02
$730.37
$41.16
$417.54
t3
$173.96
$1,111.67
$147.68
$800.61
t4
$222.88
$983.72
$176.51
$809.45
t5
$153.36
$837.10
$69.24
$594.06
t6
$146.19
$784.20
$70.24
$487.89
t7
$138.94
$848.86
$66.82
$521.07
Time
Inpatient***
t1
$315.00
$3,406.36
$130.71
$2,358.01
t2
$566.30
$9,071.37
$93.45
$1,654.38
t3
$2,997.45
$19,703.13
$1,854.68
$11,325.91
t4
$3,173.69
$14,809.44
$720.86
$5,742.17
t5
$1,697.03
$11,374.53
$400.90
$4,628.53
t6
$1,425.95
$11,967.43
$479.34
$5,169.43
t7
$1,185.19
$7,703.07
$345.73
$4,476.01
Time
Physician***
t1
$156.40
$320.98
$121.20
$250.30
t2
$166.67
$334.31
$131.08
$267.03
t3
$217.43
$391.12
$185.82
$309.58
t4
$419.98
$687.52
$221.31
$434.49
t5
$300.25
$536.57
$150.35
$312.71
t6
$251.91
$438.32
$145.46
$332.52
t7
$218.46
$401.72
$125.01
$302.37
Note: Based on working age adults without cancer, initiated on opioid therapy between 2007 and 2014, aged
between and aged between 28 and 63, had only one opioid prescription on the index and had continuous enrollment
for 29 months in a commercial insurance plan. The data were from the QuintilesIMS RWD Adjudicated Claims –
US. Differences in average expenditures between COT users and No COT users were tested using generalized
estimating equation models.
† Total expenditures are sum of emergency department, inpatient, physician and other costs and excludes
prescription drug expenditures. Other category is not displayed, thus, the sum of average inpatient, emergency
department and physician expenditures will not add up to average total expenditures.
*** p<0.001.
Abbreviations: Rx- prescription; US: United States; SD = Standard Deviation
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Table 3.4 Weighted and adjusted expenditures over time for patients with incident opioid use by
transition to chronic opioid therapy (COT) after first opioid prescription,
QuintilesIMS Real-World Data Adjudicated Claims Database - US, 2006-2015
Cost Type
COT
Index Period (Time 4)
Intercept
β
SE
p-value
β
SE
p-value
β
SE
p-value
Total (No RX)
Model 1
0.11
0.04
<0.001
0.81
0.04
<0.001
6.97
0.03
<0.001
Model 2
0.41
0.05
<0.001
0.92
0.04
<0.001
6.52
0.04
<0.001
Model 3
0.18
0.06
0.002
0.68
0.04
<0.001
6.44
0.10
<0.001
Emergency
Department
Model 1
0.38
0.06
<0.001
0.72
0.05
<0.001
4.05
0.05
<0.001
Model 2
0.31
0.06
<0.001
0.79
0.05
<0.001
3.74
0.05
<0.001
Model 3
0.01
0.08
0.884
0.42
0.05
<0.001
4.12
0.10
<0.001
Inpatient
Model 1
0.78
0.07
<0.001
0.49
0.07
<0.001
6.09
0.06
<0.001
Model 2
0.69
0.09
<0.001
0.67
0.08
<0.001
5.26
0.06
<0.001
Model 3
0.45
0.11
<0.001
0.31
0.10
0.002
5.70
0.17
<0.001
Physician
Model 1
0.27
0.02
<0.001
0.49
0.02
<0.001
4.82
0.02
<0.001
Model 2
0.18
0.03
<0.001
0.51
0.02
<0.001
4.54
0.02
<0.001
Model 3
-0.01
0.02
0.582
0.29
0.02
<0.001
4.32
0.04
<0.001
Note: This sample includes patients from QuintilesIMS RWD Adjudicated Claims – US, which were identified
between 2007 and 2014 and had enrollment between 2006 and 2015. These patients were between 28-63 years
old, without cancer, had complete demographic information available, and had only one opioid prescription on
the index date. Individual weights based on inverse probability of treatment weighting (IPTW) have been used
for this analysis. Model 1 is only adjusted for time and chronic opioid therapy; Model 2 is also adjusted for
number of other chronic conditions; Model 3 is also adjusted for number of other chronic conditions, sex, age,
region, history of drug abuse, painful conditions, benzodiazepine use, non-opioid analgesic use, and number of
unique medication classes.
Abbreviations: COT- chronic opioid therapy; Wt- weighted; AOR- adjusted odds ratio; Rx- prescription; SEsemi-robust standard error
Sig: 0 < p < 0.001 = ***, 0.001 ≤ p 0.01 = **, 0.01 ≤ p < 0.05 = *
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Figure 3.1. Difference in average total expenditures (no prescription drug costs) between chronic
opioid therapy (COT) and no COT transition using a counterfactual prediction technique
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CHAPTER 4
4

Identifying targeted continuing educational strategies to help community pharmacists
implement naloxone/buprenorphine-related medications in community pharmacies: A
state-wide survey among pharmacists

4.1

Abstract

Objective: To identify educational strategies related to opioids, buprenorphine products, and
naloxone, for pharmacists, and to determine geographic locations to reduce the risk of opioid
overdose in West Virginia (WV). Methods: A mixed-methods design included a prospective
cross-sectional survey administered in two phases [in-person (n=157) and online (n=144)] to
increase coverage of the whole state, then results were weighted based on a census of all
pharmacists in WV. Educational strategies for community pharmacists (n=179) were identified
with the Extended Parallel Process Model (EPPM), while educational objectives were based on
attitudes, dispensing/stocking practices, and knowledge gaps about opioids, naloxone, and
buprenorphine products. Qualitative responses (n=97) were also evaluated and themes were
developed. Results: Most pharmacists perceived high risk of opioid misuse in their area and high
perceived efficacy about naloxone as a treatment for opioid overdose, but many did not feel
comfortable selling naloxone. Opioid attitudes significantly differed between pharmacists in
different EPPM-assigned categories. Filling practices differed; 73% stocked
buprenorphine/naloxone and only 58% stocked buprenorphine. Pharmacists with higher
perceived efficacy of buprenorphine products were more likely to be willing to fill non-local
prescriptions. County-level disparities between actual and perceived risk for opioid misuse were
observed. In the qualitative evaluation, pharmacists listed many barriers to caring for patients
prescribed opioids or buprenorphine products. Conclusion: By tailoring educational strategies
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and objectives to pharmacists in specific geographic locations, more effective CPE can be
delivered to community pharmacists in WV to improve access to naloxone and buprenorphine
products as well as improve their understanding of addiction and psychosocial treatments.
4.2

Introduction
Opioids, both prescription and illicit, contribute to the vast majority of drug overdose

deaths, and are the leading cause of unintentional death among adults in the United States
(US).102 In 2015, West Virginia (WV) led the country with 35.5 deaths per 100,000 inhabitants –
more than twice the national average.47 Adverse effects due to prescription opioids often result in
increased emergency room visits, inpatient visits, and other healthcare utilization.2-5 Access to
both naloxone and comprehensive opioid use disorder treatment programs is very limited in the
US, especially in West Virginia (WV).103
Opioid use disorder, one of the diagnoses with highest risk for opioid overdose, can be
managed with combination of psychosocial and pharmacological treatments, including
methadone, naltrexone, and buprenorphine-containing regimens.104,105 Also, unintentional opioid
overdose deaths can be avoided with the use of naloxone.7,15,55,56 Naloxone has been approved in
many forms (e.g. intranasal, intravenous) and can completely block or reverse the effects of
opioid medications, including extreme drowsiness, slowed breathing, or loss of consciousness,
and prevent death due to opioid overdose.55,56 Expanding access in the community to
buprenorphine products and naloxone is part of a nation strategy for avoiding mortality due to
opioid overdoses.54,104,106
Naloxone delivery in a community needs a multipronged approach including two
important system strategies as described in previous research.107 First, access to naloxone must
be made available through state legislation and Boards of Pharmacy, promoted by departments of
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public health, and covered by insurers.107 In states where naloxone is already available in
community pharmacies, there is evidence of reduction in overdose related deaths.57 Second,
pharmacists and pharmacy technicians need the training and motivation to support the
implementation of increased naloxone availability in urban and rural settings.107
Pharmacists working in community pharmacies are the most widely available healthcare
professionals58 and the gatekeepers to prescription opioids as well as the medications used to
treat opioid use disorder. However, pharmacists are currently under-utilized as stakeholders to
affect change in the patients succumbing to adverse consequences of opioid abuse including drug
overdoses and deaths.54 As providing naloxone within the community is a voluntary act,
expanding capacity to provide such a service will require the buy-in from local pharmacists thus
making an assessment of pharmacists’ perceptions and providing for their educational needs a
critical component of the second strategy to increase naloxone delivery in the community.
Buprenorphine products (buprenorphine/naloxone and buprenorphine single-ingredient
products) are prescribed widely as part of a comprehensive treatment plan for use in patients
with opioid use disorders.108 Access to these products has been limited by the quantity limits
placed on the number of dosage units a wholesaler has to distribute to individual pharmacies,109
and by pharmacists having mixed attitudes as to whether or not to stock or dispense these
medications.104,110,111 The willingness to stock and dispense medications to treat opioid use
disorder as well as educational strategies used to increase this willingness, can be assessed
similarly to naloxone.
Given the extent of the opioid crisis in WV, the state can be seen as a focal point needing
evaluation regarding the capacity of community pharmacies to provide naloxone and other
opioid-related medications due to its reliance on community pharmacies to provide access to
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healthcare and its current high levels of opioid abuse and deaths.112 In our previous study of WV
community pharmacists, opioid stocking was universal, stocking of buprenorphine products was
less common, readiness to dispense naloxone was low, and general educational strategies were
identified.110 To optimize the process of providing naloxone to the communities of WV requires
an evaluation of the educational needs of pharmacists as well as their individual perceptions on
opioid-related medication efficacy, naloxone efficacy, and willingness to stock naloxone and
buprenorphine products.
The Extended Parallel Process Model (EPPM), has been used to create public
communication and education in order to increase awareness and create change to address
important health issues by appealing to the individual’s desire to control either danger or
fear.113,114 It has also been used to assign broad, educational strategies to pharmacists based on
perceptions of efficacy and risk.110 The key EPPM constructs include perceived severity,
perceived susceptibility, response efficacy, and self-efficacy.110,113-115 By assessing these four
constructs in this study, pharmacists can be placed into one of four categories defined by the
EPPM based on their perception of both the risk (High/Low) and efficacy (High/Low). Targeted
education can be created for each of these four categories to effectively tailor and deliver the
intervention to pharmacists throughout WV to have the greatest impact.
4.3

Objective
The objective of this study was to identify broad educational strategies and educational

objectives related to opioids, buprenorphine products, and naloxone, for pharmacists, and to
identify geographic locations to provide targeted continuing pharmacists education (CPE) events,
using a state-wide, representative survey of pharmacists licensed and working in WV.
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4.4

Methods

Design/Data collection
A prospective cross-sectional design with survey methodology was used to assess the
educational needs of community pharmacists in WV. A 49-item data collection instrument which
was previously created and validated in WV pharmacists110 was administered in two phases. In
the first phase, the surveys (n=157) were collected at live CPE events with preliminary results,
including validation of scales, as published previously.110 For the second phase, additional
responses (n=144 complete responses) were collected online to increase coverage of pharmacists
throughout the state. Pharmacists who were at any CPE event where surveys were collected were
not eligible for the online survey. Both phases of data collection occurred between April 2016
and April 2017.
To ensure representativeness, a census of all pharmacists licensed and working in WV
was collected. With the agreement of the West Virginia Board of Pharmacy (WVBOP), three
researchers (JDT, XZ, and ND) collected demographic information [email, gender, date or birth,
current status (active/inactive), and county of employer] of all pharmacists licensed and working
in WV. This information was up-to-date as of the most recent license renewal in July 2016. This
is the first time the effort has been made to determine which pharmacists work in WV, as
opposed to those licensed in WV but working elsewhere. Email addresses were used to send the
electronic version of the survey to pharmacists who did not attend a live CPE event earlier in the
year using Qualtrics’s anonymous data collection option. The study, survey, and census data
collection were approved by the West Virginia University Institutional Review Board.
Measures
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Components of the survey have been described, in detail, in our previous publication.110
Other measures for this study not previously described are included below:
EPPM Category (High Risk/High Efficacy; High Risk/Low Efficacy; Low Risk/High Efficacy;
Low Risk/Low Efficacy): The main constructs used in the EPPM (1- severity, 2- susceptibility, 3response efficacy, and 4- self-efficacy) were assessed with (1) opioid adverse event scale, (2)
perceived misuse of opioids, (3) efficacy of naloxone to reverse an opioid overdose, and (4)
ability to dispense naloxone at a community pharmacy, respectively. For the continuouslymeasured constructs used to assess Risk (severity and susceptibility), the median score was used
to categorize pharmacists (High or Low). For categorically-measured constructs (response
efficacy and self-efficacy) a response of 4 or greater on a 5-point Likert-type scale which
indicated “Agree” or “Strongly Agree” was used to categorize pharmacists based into High
Efficacy or Low Efficacy groups. If a pharmacist had high in either severity/susceptibility or
response efficacy/self-efficacy, they were considered as having a High Risk or High efficacy,
respectively.
Buprenorphine perceived efficacy scale consisted of three items adapted from the Clinicians’
Attitudes and beliefs about Opioids Survey’s (CAOS) perceived effectiveness subscale, for use
with pharmacists.116
Drug-overdose death rate (by county): To assess broader, county-level risk, the age-adjusted
drug-overdose mortality rates for each county in WV102 were categorized as high (>30 per
100,000 population) or low (≤30).
Data analyses
Census data from the WVBOP were manually entered into an Excel (Microsoft, 2016)
spreadsheet by two of the researchers (JDT and XZ). For the electronic survey responses,
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Qualtrics data output was imported into SPSS (v22, IBM, 2016) for cleaning and converted for
use in SAS (v9.4, Cary, NC) for analysis. Principal component analysis (PCA) and Cronbach’s
alpha was assessed for the buprenorphine efficacy scale. Principal component analysis (PCA) is
a data reduction technique that selects a subset of variables based on correlation or covariance
(validity). Cronbach’s alpha is a measure of internal consistency of the scale (reliability).
Descriptive (e.g., frequencies, means, and standard deviations) and inferential statistics
were used to describe the data from this cross-sectional research survey. Chi-square analysis
were used to examine the differences in the community pharmacist subgroups based on the
EPPM constructs, geography, and stocking/dispensing practices. If expected cell sizes were less
than five for at least 20% of cells, exact statistics were assessed (e.g. Fisher’s Exact Test). All
statistical analyses assumed a significance level of alpha = 0.05. The study data were analyzed
using SAS (v9.4; Cary, NC).
Sample weighting
Ideally, the sample of pharmacists represents the population from which they were
selected. However, in our study, we observed significant differences in the age distribution of
respondents and the WVBOP sampling frame data. There were 2,058 pharmacists licensed and
working in WV, as of the most recent license renewal in July 2016.; 9.6% of the state
pharmacists were in the age group 24-29 while 15.6% of the study sample was in that age group.
Therefore, we created sampling
weights based on and age of pharmacists licensed and working in WV. These weights were
calculated as inverse probability using the age distribution of the WVBOP sampling frame.
However, results were presented both before and after applying individual weights.
Qualitative Assessment
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The open-ended items from the survey’s written responses were evaluated using
qualitative methods. Each response was entered into ATLAS.ti (version 1.0.51), a program used
for qualitative assessment and coding. Two researchers (JDT and XZ) reviewed the responses
independently to identify codes for qualitative assessment. The codes were discussed and agreed
upon through consensus with a third researcher (ND) serving as an arbitrator and reviewer.
Codes were then assigned to the responses independently and agreed upon. The codes were
grouped into themes which were developed using the Grounded Theory approach.117
4.5

Results
Overall, 301 pharmacists responded to the survey either in person or on-line, and Table 4.1

compares the sample of survey respondents to the population of WV pharmacists. There were
172 community pharmacists who completed the survey.). Age-weighted and unweighted
characteristics of responding pharmacists can be seen in Table 4.2, and the unweighted sample
was mostly female (50.3%), first licensed after 1990 (66.9%), worked in a fulltime (76.0%) staff
position (55.3%), in counties with drug-overdose death rates of ≤ 30 per 100,000 population.
The descriptive information on the values of the constructs used in the EPPM (severity,
susceptibility, response efficacy, and self-efficacy), opioid attitudes, naloxone attitudes, stocking
practices, filling practices, and whether the respondent left information to be included in the
qualitative assessment (56.2%) was provided in Table 4.2. Of note, pharmacists in WV believed
that opioids are being over-prescribed in their county (82.7%), agreed that they are helping to
curb opioid diversion by declining to fill some prescriptions for opioids (73.2%), but 41.5%
agreed they were harming patients who have legitimate pain issues. There was a large gap in
stocking practices between opioids and buprenorphine products with all community pharmacists
stocking opioids, but only 73.0% stocked buprenorphine/naloxone and only 58.0%
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buprenorphine. Along these same lines, more pharmacists would refuse to fill a prescription for
an out of local area or out-of-state buprenorphine prescription (77.8% and 73.5%, respectively),
compared to an opioid prescription (58.4% and 53.9%, respectively). Most pharmacists agreed
that they are not adequately trained to use naloxone over the counter (67.6%).
The EPPM constructs, from which educational strategies are defined, were used to place
pharmacists into four categories [High Risk/High Efficacy (HR/HE); High Risk/Low Efficacy
(HR/LE); Low Risk/High Efficacy (LR/HE); or Low Risk/Low Efficacy (LR/LE)]. After
weighting the sample for age, the majority of community pharmacists were categorized as having
HR/HE (56.0%). The HR/HE group was more likely to be staff pharmacists or managers
compared to owners (p<0.05). Opioid attitudes significantly differed between pharmacists in
different EPPM-assigned categories as well. The HR/HE group was less likely to think chronic
opioids were necessary for their chronic non-cancer pain patients (p<0.001), but were more
likely to neither agree nor disagree that opioids were being prescribed in their county (p<0.01).
Also, pharmacists in the HR/HE group were less likely to agree that letting patients purchase
naloxone over the counter will increase opioid overdosing (p<0.05). Other comparisons can be
seen in Table 4.3.
To identify educational objectives based on buprenorphine products, perceived efficacy
and misuse of buprenorphine products were compared to county characteristics and
stocking/dispensing practices of these products. The newly-validated three-item buprenorphine
efficacy scale for pharmacists had all three items load on one component (>0.8), was reliable
with a Cronbach’s α = 0.79, and had a mean of 7.88 (SD=2.72). Overall, WV pharmacists on
average estimated that 30.7% of prescriptions for buprenorphine products were misused or
abused. Lower perceived buprenorphine efficacy was associated with a lack of willingness to fill
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a non-local (p<0.001) or out-of-state (p<0.01) prescription for those products. Perceived
buprenorphine misuse was associated with declining a prescription for not being for a legitimate
medical purpose (p<0.05). Other comparisons for buprenorphine constructs can be seen in Table
4.4.
Qualitative responses were assessed for the 97 community pharmacists in WV who
provided comments on the open-ended items. A common theme was that opioids are being
overprescribed in general, and in their local areas. Another frequent theme was that there is a
responsibility on the prescriber since pharmacists are not able to make opioid regimen changes.
Table 4.5 has quotations from pharmacists used to categorize qualitative responses into themes
relating to barriers to making available opioids, naloxone, or buprenorphine products. There
were many reasons for refusing prescriptions that included need for education (e.g. “All
healthcare providers need more education in handling patients with pain…”) and stigma towards
patients (e.g. “…it’s very hard to determine who has a legitimate need due to the stigma of
opioid use”). In addition to reasons for refusing to fill prescriptions, pharmacists expected
buprenorphine regimens to be de-escalated regularly (e.g. “it is very rare that I see the
[buprenorphine products] dose decreased”).
4.6

Discussion
The Extended Parallel Process Model can be used to help tailor educational strategies for

pharmacists to improve access to naloxone and buprenorphine products as well as their
understanding of addiction and psychosocial treatments. Although the majority of the
respondents surveyed expressed concerns about opioid overuse in their counties, most of them
were not adequately trained to dispense naloxone over the counter. There were significant
differences in opioid, naloxone, and buprenorphine product attitudes among community
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pharmacists, which can be targeted in different CPE events. Educational objectives can be
determined based on the gaps in knowledge.
Two components are needed to deliver effective CPE: educational materials developed
based on need and target areas where an impact can be made. The EPPM has been used to
identify board educational strategies for pharmacists, that takes into account their ability to be
influenced by certain components of the EPPM (namely, affect and cognition).110,115 According
to this conceptual framework, most of the respondents had High Risk and High Efficacy levels
(HR/HE) and they will be responsive to a call to action and information on the infrastructure
available to deliver naloxone through their community pharmacies.115 Whereas pharmacists with
Low Efficacy or Low Risk, strategies will need to focus on their ability to act and their role to
play, or the actual risk in their community of adverse consequences of opioids, respectively.110,115
Identifying counties to provide CPE can be based on the disparity between actual (based
on drug death rate) and perceived risk. For example, based on our state-wide survey results,
pharmacists in Raleigh County (7% of all pharmacists licensed and working in WV) were more
likely to have a low perceived risk, but the actual drug-overdose death rate in the county was
over 30 deaths per 100,000 population.102 This is one location where risk-based education can be
emphasized, to have a greater impact. Alternatively, another county, Mingo County, has high
actual risk and the pharmacists who responded indicated a high perceived risk, thus risk-based
education118 might not be as impactful.
For patients with chronic painful conditions or patients with opioid use disorders to have
access to their medications, pharmacists working in community pharmacies must be willing to
stock and fill those medications. Lower perceived efficacy or suspected misuse of these
medications made it less likely that the pharmacist would either stock or fill prescriptions for
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these products. To this point, quantitative results were reinforced by the qualitative responses
provided by the pharmacists. Community pharmacists emphasized the need for increased
education on pain management and effective communication between all stakeholders (patients,
pharmacists, prescribers, and the government regulators).
The availability of buprenorphine is a problem throughout the US, especially in WV.
Only certain prescribers can write prescriptions for these medications, and patients seeking
treatment for opioid use disorder far outpaces the number of spots available for treatment in
high-quality centers.119 Buprenorphine products are also limited by wholesalers who report high
use pharmacies and prescribers to the FDA and DEA.109 Due to the scarcity of these products,
some patients must travel great distances to fill their legal prescription. Pharmacists can be
compounding this problem because they are worried about out-of-state and out of local area
prescriptions. Again, the qualitative responses reinforced the quantitative results, that
pharmacists are worried about misuse and abuse of buprenorphine products. Many pharmacists
noted that they expected buprenorphine regimens to have tight oversight with regular dose deescalation. The treatment paradigm for opioid use disorder is changing so that patients are treated
as though they have a chronic illness.120 Some of these patients will have better outcomes in
terms of recovery with fewer relapses if buprenorphine regimens are maintained long-term.
Education for pharmacists that focuses on these use-cases can possibly decrease the perceived
misuse and increase perceived efficacy of these products.
Providing education on pain management, use of naloxone in the community, opioid use
disorder, and how to improve communication with both prescribers and patients will be
beneficial to pharmacists and patients seeking care. Education on addiction may help reduce
stigma and increase a sense of the broad range of psychosocial and pharmacological treatment
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options. Future research can focus on providing pharmacists with tailored education to reduce
stigma and encourage participation to dispense buprenorphine and naloxone to help people
suffering from opioid use disorder and potential drug overdose. These future studies can be
guided by the Kirkpatrick model used to evaluate training programs.121 Using this model, four
factors would be assessed throughout a follow-up period starting with reaction to the tailored
intervention, then an evaluation of learning after the training program. Longer-term evaluations
of tailored educational interventions would assess changes in behavior and impact to the
community.
This is the first study to identify targeted continuing educational intervention for
community pharmacists based on the EPPM conceptual framework. These education
components can be used to affect change in terms of availability of naloxone and buprenorphine
products. There were many strengths to this study including the use of a population census of
pharmacists licensed and working in WV to generalize the survey results for the entire state of
WV. This study collected the first functional census of WV pharmacists to ensure state-wide
representativeness of the findings. Also, this population-based survey of pharmacists focused on
currently under-utilized providers who can play a critical role in preventing opioid-related
overdose and death. This study had a few potential limitations. Surveys were collected over the
period of one year, so pharmacists could have received education on naloxone through their
employers or the state. However, current naloxone education in WV is not tailored to
pharmacists and focuses on emergency administration. The surveys were collected via two
modes of data collection, but the sample was assessed for representativeness and weighted based
on age to mitigate this limitation. Survey research has certain potential limitations associated
with the data collection process. The validity of the results may be affected by the usual
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limitations of self-report questionnaires and thus may not fully reflect the respondents’ beliefs,
attitudes, or actual practices.
4.7

Conclusion
West Virginia community pharmacists’ stocking and dispensing of naloxone and

buprenorphine products are affected by their beliefs about efficacy, misuse, and abuse of these
products. Most pharmacists felt unprepared to dispense naloxone over the counter. Using
targeted educational strategies, locations, and objectives, more effective CPE can be delivered to
community pharmacists in the state to improve access to critical, potentially life-saving,
medications.
4.8
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Table 4.1. Characteristics of the sample of survey respondents compared to the population of pharmacists licensed
and working in West Virginia as of July 2016.
Sample
Population
All
n=301
Column %
n=2,058
Column %
Age (years)
24-29
47
15.61
197
9.57
30-34
46
15.28
319
15.50
35-39
40
13.29
290
14.09
40-44
29
9.63
302
14.67
45-49
28
9.30
251
12.20
50-54
29
9.63
190
9.23
55-59
28
9.30
186
9.04
60-64
24
7.97
170
8.26
65+
22
7.31
153
7.43
Missing
8
2.66
--Gender
Female
154
51.16
1,073
52.14
Male
146
48.50
985
47.86
Missing
1
0.33
--Notes: Survey data was collected between April 2016 and April 2017 from pharmacists licensed and working in WV. Population
data was collected from the WV Board of Pharmacy license renewal forms on site and is up-to-date as of July 2016. Countylevel information was collected for both the sample and population, but placed in categories for display purposes.

62

Table 4.2. Description of the sample of community pharmacists licensed and working in WV that responded to
the survey, weighted by age based on the state-wise census of pharmacists.
All
n = 172
Wt. %
Pharmacist and Workplace Characteristics
Gender (n=171)
Female
86
51.6
Male
85
48.3
Year first licensed
1980 and before
26
14.8
1981-1990
31
17.0
1991-2000
44
32.4
2001 and after
71
35.8
Position (n=170)
Owner or Part owner
19
11.8
Management (including Pharmacist in Charge)
57
34.3
Staff
94
53.9
Work schedule (n=171)
Fulltime
130
76.3
Part-time
41
23.7
Region (US Congressional District) (n=170)
First (Northern)
69
39.5
Second (Central and Eastern)
52
32.8
Third (Southern)
49
27.7
Drug-related deaths in county of workplace (n=170)
High (>30)
62
35.2
Low (≤30)
108
64.8
EPPM Constructs (n=172)
Severity: Opioid adverse event scale score
Mean = 23.1
SD = 3.5
Susceptibility: Perceived misuse of opioids at community pharmacy
Mean = 29.5
SD = 24.5
Response efficacy: Efficacy of naloxone
High
130
Low
42
Self-efficacy: Dispense naloxone at community pharmacy
High
39
Low
133
Opioid Attitudes
Opioid perceived efficacy scale (n=168)
Mean = 14.9
SD = 3.5
Taking opioids for long periods of time is necessary for many of my chronic
non-cancer pain patients. (n=171)
Disagree
90
52.0
Neither
33
18.9
Agree
48
29.1
Long-term use of opioids is overprescribed for patients with chronic non-cancer
pain.
Disagree
8
5.0
Neither
11
6.7
Agree
153
88.3
Continued
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Table 4.2. Description of the sample of community pharmacists licensed and working in WV that responded to
the survey, weighted by age based on the state-wise census of pharmacists.
All
n = 172
Wt. %
Some clinicians in my county prescribe opioids to their patients with chronic
non-cancer pain for long periods of time too frequently.
Disagree
4
2.8
Neither
14
9.5
Agree
154
87.7
Opioids are being overprescribed by practitioners in my county.
Disagree
9
5.6
Neither
19
11.7
Agree
144
82.7
Pharmacists are curbing opioid diversion and/or abuse by declining to fill some
prescriptions for opioids.
Disagree
20
11.7
Neither
26
15.1
Agree
126
73.2
Pharmacists are harming some patients who have legitimate pain issues by
declining to fill some prescriptions for opioids. (n=171)
Disagree
60
35.2
Neither
40
23.3
Agree
71
41.5
Naloxone Attitudes
Letting patients purchase naloxone over the counter will
increase opioid overdosing. (n=171)
Disagree
53
29.1
Neither
51
30.3
Agree
67
40.6
I do not believe that I am adequately trained in the use of
naloxone over the counter.
Agree
114
67.6
Unsure
29
16.2
Disagree
29
16.2
Stocking Practices
Stock opioids (n=171)
Yes, stocked
171
100.0
Not stocked
0
0.0
Stock buprenorphine/naloxone (n=171)
Yes, stocked
125
73.0
Not stocked
46
27.0
Stock buprenorphine (n=170)
Yes, stocked
97
58.0
Not stocked
73
42.0
Filling Practices
Fill a non-local (outside a 20-mile radius of your pharmacy) prescription for opioid
Would not fill
97
58.4
Would fill
75
41.6
Fill an out-of-state prescription for an opioid
Would not fill
94
53.9
Would fill
78
46.1
Continued
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Table 4.2. Description of the sample of community pharmacists licensed and working in WV that responded to
the survey, weighted by age based on the state-wise census of pharmacists.
All
n = 172
Wt. %
Fill a non-local (outside a 20-mile radius of your pharmacy) prescription for
buprenorphine/naloxone (n=166)
Would not fill
127
77.8
Would fill
39
22.2
Fill an out-of-state prescription for a buprenorphine/naloxone (n=164)
Would not fill
122
73.5
Would fill
42
26.5
Provided Qualitative Response
Responded to at least one qualitative item
No
75
43.8
Yes
97
56.2
Notes: This sample includes patients a survey of pharmacist licensed and working in West Virginia as of July 2016. Some
categories were collapsed. Weighted N were rounded to nearest whole person. EPPM categories were created using
unweighted measures of central tendency, so weighted results are not presented.
Abbreviations: Wt. % = weighted percentage
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Table 4.3. Extended Parallel Process Model (EPPM) categories for a sample of community pharmacists licensed
and working in WV, weighted by age based on the state-wise census of pharmacists
High Risk/
High Risk/
Low Risk/
Low Risk/
High Efficacy
Low Efficacy
High Efficacy
Low Efficacy
Wt. n
Wt. %
Wt. n
Wt. %
Wt. n
Wt. %
Wt. n
Wt. %
Sig.
All

100

Gender
Female
Male
Year first licensed
1980 and before
1981-1990
1991-2000
2001 and after
Position
Owner or Part
owner
Management
(including
Pharmacist in
Charge)
Staff
Work schedule
Fulltime

56.0
31
17.4
37
20.6
Pharmacist and Workplace Characteristics

11

6.0

58
42

63.5
48.7

15
16

16.5
18.5

14
23

15.0
26.9

5
5

4.9
6.0

17

65.6

2

7.6

6

23.0

1

3.8

20

66.4

5

17.7

3

9.5

2

6.3

27
35

46.6
55.5

13
10

23.2
16.0

14
14

24.1
21.9

3
4

6.0
6.6
*

6

27.1

3

15.3

9

40.9

3

16.7

40

66.8

10

16.0

8

12.8

3

4.4

52

54.6

18

19.1

21

21.6

5

4.8

77

57.4

23

16.8

28

20.8

7

5.0

8

19.6

9

20.6

4

9.3

14

23.1

12

19.2

5

7.5

Part-time

21
50.5
Drug-related deaths in county of workplace
High (>30)
31
50.2
Low (≤30)
66
58.2

17
14.7
25
21.9
6
5.3
Opioid Attitudes
Taking opioids for long periods of time is necessary for many of my chronic non-cancer pain patients.
Disagree
56
61.0
22
24.4
10
11.1
3
3.5
Neither
Agree

20

59.2

2

6.6

7

21.2

23
44.1
6
12.2
19
37.8
Long-term use of opioids is overprescribed for patients with chronic non-cancer pain.
Disagree
3
32.5
0
0.0
6
67.5
Neither

7

54.9

0

0.0

Agree

91
57.3
31
19.6
Opioids are being overprescribed by practitioners in my county.
Disagree
3
27.0
0
0.0
Neither
16
77.9
3
12.5
Agree

81

54.9

28

19.2

Continued
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4

13.0

3

5.8

***

**

3

28.8

0
2

0.0
16.4

28

17.6

9

5.5
**

7

73.0

0

0.0

2
28

9.6
18.7

0
11

0.0
7.2

Table 4.3. Extended Parallel Process Model (EPPM) categories for a sample of community pharmacists licensed
and working in WV, weighted by age based on the state-wise census of pharmacists
High Risk/
High Risk/
Low Risk/
Low Risk/
High Efficacy
Low Efficacy
High Efficacy
Low Efficacy
Wt. n
Wt. %
Wt. n
Wt. %
Wt. n
Wt. %
Wt. n
Wt. %
Sig.
All
100
56.0
31
17.4
37
20.6
11
Pharmacists are curbing opioid diversion and/or abuse by declining to fill some prescriptions
for opioids.
Disagree
13
63.4
1
4.8
7
31.8
0
Neither
14
51.9
5
17.1
4
15.6
4
Agree
73
55.7
25
19.5
26
19.9
7
Pharmacists are harming some patients who have legitimate pain issues by declining to fill some
prescriptions for opioids.
Disagree
37
60.0
13
21.2
9
14.6
3
Neither
21
52.0
8
18.5
8
19.5
4
Agree
41
56.1
10
13.9
18
24.7
4
Naloxone Attitudes
Letting patients purchase naloxone over the counter will increase opioid overdosing.
Disagree
32
61.6
5
9.8
14
27.5
Neither
Agree

34

64.6

8

14.6

6

12.0

32
44.9
18
25.3
16
22.3
I do not believe that I am adequately trained in the use of naloxone over the counter.
Agree
66
54.3
24
20.2
22
18.4
Unsure

21

73.3

Disagree

13

45.6

1

3.6

5

16.1

6
19.5
10
34.9
Filling Practices
Fill a non-local (outside a 20-mile radius of your pharmacy) prescription for opioid
Will not fill
59
56.3
19
18.2
21
20.2
Will fill
41
55.5
12
16.3
16
21.2
Fill an out-of-state prescription for an opioid
Will not fill
52
54.1
Will fill
48
58.3

6.0

0.0
15.4
5.0

4.2
10.0
5.3
*

0

1.2

5

8.7

5

7.6

9
2

7.2
6.9

0

0.0

5

5.3

5

7.0

19

19.7

17

18.2

8

8.0

12

14.7

19

23.4

3

3.6

Notes: This sample includes patients a survey of pharmacist licensed and working in West Virginia as of July 2016. Some
categories were collapsed. Due to small expected cell sizes, exact tests were used to verify any significant results. Respondents in
the sample with missing age values were given a weight of one for the weighted analysis. Weighted N were rounded to nearest
whole person.
Significance: 0 ≤ p < 0.001 = ***, 0.001 ≤ p 0.01 = **, 0.01 ≤ p < 0.05 = *, 0.05 ≤ p < 0.1 = +
Abbreviations: Wt = weighted
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Table 4.4. Perceived efficacy and misuse/abuse of buprenorphine prescription products by community factors and
pharmacist practices in WV.
Buprenorphine Efficacy
Estimated Misuse/Abuse of
Scale Score
Buprenorphine Products (%)
Mean =
SD =
n=
Mean =
SD =
n=
All
7.88
2.72
169 p value
Sig
30.74
31.56
140 p value Sig
0.6314
0.0796 +
Drug death in county
High
7.77
2.96
61
36.94
32.22
53
Low
7.98
2.59
106
27.28
30.77
86
0.0794 +
0.1056
Stocking buprenorphine products
Yes
8.10
2.84
123
32.64
31.21
121
No
7.27
2.28
45
19.72
32.61
18
Willing to fill non-local buprenorphine
<0.001 **
0.8613
product
Yes
9.15
2.70
39
30.44
28.02
39
No
7.49
2.61
124
31.48
33.00
99
Willing to fill out of state buprenorphine
0.0023 **
0.6765
product
Yes
9.00
2.80
41
29.71
29.91
42
No
7.51
2.62
120
32.17
32.41
95
Declined prescription for buprenorphine
for not being for a legitimate medical
0.0635 +
0.0207 *
purpose
Yes
7.15
2.78
40
41.58
31.80
38
No
8.09
2.71
113
27.64
30.91
98
Notes: This sample includes patients a survey of pharmacist licensed and working in West Virginia as of July 2016. Some categories
were collapsed.
Significance (Sig): 0 ≤ p < 0.001 = ***, 0.001 ≤ p 0.01 = **, 0.01 ≤ p < 0.05 = *, 0.05 ≤ p < 0.1 = +
Abbreviations: SD = Standard Deviation

68

Table 4.5. Barriers to the availability of opioid, naloxone, and buprenorphine product distribution through
community pharmacies, among pharmacists licensed and working in WV.
Example Quotations
Reasons for refusing
prescriptions
Out of state or
“All pharmacists in our county are very picky about out of county or out of
local area
state controlled prescriptions.”
“Concerned about not being able to track patients’ drug history across other
states.”
“…we don’t want to fill anymore opioids prescriptions from patients we have
never filled before. Not that the prescriptions are fraudulent or have anything
wrong with them.”
Need for
effective
communication

“It is necessary though to form a strong patient-pharmacist relationship in
order to ascertain any forms of abuse”
“The problem is even irresponsible doctors have patients with legitimate
pain.”
“…the physician-patient medical relationship is impossible to prove from the
pharmacy”

Need education
on pain
management

“More educational programs are necessary for doctors”
“Patients are not educated enough on how addictive opiates are”
“All healthcare providers need more education in handling patients with
pain…”

Stigma on
patients

“…it’s very hard to determine who has a legitimate need due to the stigma of
opioid use.”
“…I am now stereotyping every patient with an opioid prescription as a drug
addict. I wish we didn’t even carry opioids at our pharmacy anymore.”

Perceptions of abuse of
buprenorphine products
No reduction in
dose

“It is very rare that I see the [buprenorphine products] dose decreased.”
“…patients are prescribed [buprenorphine products] without much oversight
or without changes in dosages for long periods of time.”
“… [prescribers] never reduce dose…”

Association with
patient demeanor

“I feel that [buprenorphine product] is more abused and sold on the street
than taken to treat opioid dependence.”
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CHAPTER 5
5
5.1

Discussion of findings and research implications
Summary of Findings
This dissertation had many unique components. This is the first study to identify incident

COT in a nationally-representative sample of working-aged adults, who were initiated on opioid
therapy. This is an important group to focus on because of the impact on productivity and their
increased likelihood to receive opioid therapy when they experience pain.25 As a rate, we found
that 13 out of 1000 patients with initial prescription of opioids transitioned to COT. As
demonstrated in this study, a smaller set of more easily assessed factors at initiation (duration of
action, standardized dose, parent opioid, age, sex) can be used to gauge the risk of transition to
COT. Our predictive models identified four leading predictors that increased the risk of transition
to COT by at least four times. These were: duration of action, type of parent opioids, drug use
disorders, and painful conditions.
The patients who do transition to COT have an increase in healthcare utilization and
expenditures, as we found in the second aim of this study. Most trajectories of healthcare
utilization and expenditures throughout the follow-up periods were different between COT and
non-COT users. Any intervention focused on curbing transition to COT has the potential to
prevent inpatient use and can lead to cost savings for the payer(s).
Despite the consequences of transitioning to COT, the answer is not to withhold care. In
the third aim of this study, all community pharmacies surveyed stocked opioid medications, but
fewer stocked naloxone or buprenorphine products. The Extended Parallel Process Model can be
used to help tailor educational strategies for pharmacists to improve access to naloxone and
buprenorphine products as well as their understanding of addiction and psychosocial treatments.
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The stocking and dispensing of naloxone and buprenorphine products by community pharmacists
in WV are affected by their beliefs about efficacy, misuse, and abuse of these products. Using
targeted educational strategies, locations, and objectives, more effective CPE can be delivered to
community pharmacists in the state to improve care.
5.2

Strengths and Limitations

5.2.1 Strengths
Strengths of this study include the availability of a nationally-representative sample of the
US commercially-insured population, following individuals across multiple providers and
settings, use of statistical and machine learning predictive methods, and availability of dates so
that we could identify first, index opioid prescription. Also, this study assessed incident COT,
which other studies have not distinguished from prevalent use of chronic or long-term opioid
therapy. By using the NLM programs RxMix and RxNav to identify clinical drug components,
the duration of action and parent opioid for each prescription could be identified, which allowed
for more granular assessment of the opioid regimen using claims data. Finally, the data spanned
many unique insurers and plan types, which allowed for the tracking of patients through time and
to determine an opioid-free period of 12 months.
The longitudinal design with repeated measures of utilization and expenditures for
patients with and without transition to COT allowed for an assessment of baseline utilization and
expenditures in the second aim. This allowed us to control for baseline profiles in terms of
utilization, expenditures, and patient complexity. Furthermore, we applied robust statistical
methods to control for observed selection bias.
The conceptual framework (EPPM) was used to help tailor educational strategies for
pharmacists to improve access to naloxone and buprenorphine products as well as their
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understanding of addiction and psychosocial treatments These education components can be
used to affect change in terms of availability of naloxone and buprenorphine products. This study
collected the first functional census of WV pharmacists to ensure state-wide representativeness
of the findings. Also, this population-based survey of pharmacists focused on currently underutilized providers who can play a critical role in preventing opioid-related overdose and death.
5.2.2 Limitations
The study also has some potential limitations. Prescription claims do not have
information on variables such as pain, socio-economic status, social capital, medication beliefs,
and response to pain treatment, which may affect transition to COT. Also, claims data allow for
the identification of prescription medication, but not actual use of these medications. There are
limitations of the predictive modeling results as well. The models were assessed in a unique
subsample (testing data) of the overall sample. However, the validity of the model and its
predicted probabilities will be more generalizable if applied to a different sample of patients,
potentially from other commercial healthcare plans. The importance of factors could change, and
even be improved if other types of information were added to the dataset (e.g. social
determinants of health, medication use behaviors, prescriber characteristics).
Surveys were collected over the period of one year, so pharmacists could have received
education on naloxone through their employers or the state. However, current naloxone
education in WV is not tailored to pharmacists and focuses on emergency administration. The
surveys were collected via two modes of data collection, but the sample was assessed for
representativeness and weighted based on age to mitigate this limitation. Survey research has
certain potential limitations associated with the data collection process. The validity of the results
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may be affected by the usual limitations of self-report questionnaires and thus may not fully
reflect the respondents’ beliefs, attitudes, or actual practices.
5.3

Conclusions and Implications of the study
Our study findings suggest that an individual’s transition to COT can be predicted by

information readily available in a clinical setting such as the initial opioid regimen
characteristics, past history of drug use disorder, and painful conditions. Predictive models can
be used to aid clinician’s decision making; develop real-time predictions about future risk of
transition to COT; influence policy, prescriber education, and prescription monitoring programs;
and can applied to other patient populations. This transition to COT can also place a significant
economic burden on payers and patients in terms of healthcare utilization and expenditures.
Despite having similar baseline values, patients making the transition to COT had persistently
high levels of utilization and expenditures even after 12 months following the transition to COT.
The period of time after incident opioid prescription, but before COT, is an important time for
intervention for payers and clinicians.
Providing care for patients using, misusing, or even abusing opioid medications can be
difficult, especially in rural states throughout the US. WV community pharmacists’ stocking and
dispensing of naloxone and buprenorphine products are affected by their beliefs about efficacy,
misuse, and abuse of these products. Most pharmacists felt unprepared to dispense naloxone over
the counter. Using targeted educational strategies, locations, and objectives, more effective CPE
can be delivered to community pharmacists in the state to improve access to critical, potentially
life-saving, medications.
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7
7.1

Appendices
Supplemental Information- Chapter 2: Predictors of transitioning to incident chronic opioid therapy among workingaged adults

Supplemental Table 7.1.1. Logistic regression with adjusted odds ratio (AOR) and 95% confidence interval (95%CI) for patients with incident opioid use by transition to
chronic opioid therapy after first opioid prescription, using QuintilesIMS Real-World Data Adjudicated Claims - US, 2006-2015
Model 1 in
Model 1 in
Fully-adjusted model in
Fully-adjusted model in Test
Training/Validation subsample
Test subsample
Training/ Validation subsample
subsample
AOR
95% CI Sig
AOR
95% CI Sig
AOR
95%CI Sig
AOR
95% CI Sig
Age (continuous)
1.02
[1.02,1.02] ***
1.02
[1.02,1.03] ***
1.02
[1.01,1.02] ***
1.02
[1.01,1.03] ***
Male vs. Female
1.45
[1.37,1.53] ***
1.43
[1.27,1.60] ***
1.50
[1.41,1.59] ***
1.46
[1.30,1.65] ***
Highly likely chronic pain
5.98
[5.01,7.11] ***
5.91
[4.18,8.20] ***
5.59
[4.68,6.66] ***
5.47
[3.89,7.68] ***
vs. None
Likely chronic pain vs.
2.15
[2.02,2.27] ***
2.08
[1.84,2.34] ***
2.08
[1.96,2.21] ***
2.02
[1.79,2.28] ***
None
Arthritis vs. None
1.83
[1.68,1.98] ***
1.92
[1.63,2.25] ***
1.78
[1.64,1.93] ***
1.86
[1.58,2.20] ***
Hydrocodone vs. Codeine
2.19
[1.87,2.58] ***
2.04
[1.49,2.87] ***
2.15
[1.83,2.52] ***
1.97
[1.42,2.73] ***
Oxycodone vs. Codeine
2.52
[2.13,3.01] ***
2.70
[1.92,3.90] ***
2.53
[2.13,3.02] ***
2.67
[1.87,3.81] ***
Tramadol vs. Codeine
7.03
[5.99,8.31] ***
7.59
[5.53,10.74] ***
6.79
[5.77,8.01] ***
7.26
[5.20,10.13] ***
All other opioids vs.
6.03
[4.68,7.75] ***
5.71
[3.38,9.59] ***
5.89
[4.57,7.60] ***
5.64
[3.34,9.53] ***
Codeine
Long-acting vs. Immediate
16.01
[13.17,19.42] ***
12.43
[8.13,18.83] ***
16.08
[13.21,19.57] ***
12.28
[8.06,18.72] ***
release
Moderate vs. Low dose†
0.52
[0.47,0.57] ***
0.45
[0.37,0.55] ***
0.52
[0.47,0.57] ***
0.45
[0.37,0.54] ***
High vs. Low dose†
0.52
[0.41,0.65] ***
0.71
[0.47,1.05]
0.52
[0.41,0.65] ***
0.68
[0.45,1.02]
Very high vs. Low dose†
1.77
[1.40,2.22] ***
1.27
[0.73,2.08]
1.72
[1.36,2.17] ***
1.24
[0.74,2.08]
Benzodiazepine
2.06
[1.90,2.22] ***
1.99
[1.69,2.33] ***
1.82
[1.67,1.97] ***
1.82
[1.54,2.16] ***
prescription vs. None
Drug use disorder
8.17
[6.75,9.83] ***
4.96
[3.13,7.58] ***
6.32
[5.17,7.73] ***
4.02
[2.53,6.40] ***
diagnosis vs. None
Self vs. Spouse
--0.96
[0.88,1.05]
0.84
[0.71,1.01]
Unknown vs. Spouse
--1.30
[1.19,1.42] ***
1.19
[1.00,1.43]
Continued
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Other vs. Spouse
--0.82
[0.70,0.97]
*
0.93
[0.67,1.28]
PPO vs. HMO
--1.06
[0.96,1.16]
1.20
[0.99,1.46]
Other‡ vs. HMO
--0.86
[0.77,0.96]
**
1.06
[0.84,1.34]
Midwest vs. East
--1.13
[1.03,1.24]
**
1.28
[1.06,1.55]
**
South vs. East
--1.21
[1.11,1.32] ***
1.31
[1.08,1.58]
**
West vs. East
--1.02
[0.90,1.15]
1.28
[0.99,1.64]
Cardio-metabolic condition
--1.17
[1.10,1.25] ***
0.90
[0.79,1.03]
vs. None
Mental illness vs. None
0.78
[0.67,0.91]
--1.34
[1.25,1.45] ***
**
Asthma vs. None
--0.87
[0.76,1.00]
*
0.85
[0.64,1.13]
COPD vs. None
--1.24
[0.92,1.67]
1.66
[0.92,3.02]
Dementia vs. None
--1.33
[0.84,2.11]
1.75
[0.73,4.17]
Hepatitis vs. None
--1.55
[1.18,2.04]
**
1.94
[1.19,3.15]
**
Osteoporosis vs. None
--1.44
[1.14,1.83]
**
1.04
[0.59,1.83]
Tobacco vs. None
--1.45
[1.29,1.64] ***
1.34
[1.04,1.73]
*
Any alcohol abuse vs. None
--0.93
[0.73,1.18]
0.78
[0.45,1.34]
Acute pain condition vs.
--0.86
[0.67,1.10]
0.95
[0.59,1.53]
None
Stimulant prescription vs.
--1.65
[1.40,1.95] ***
1.33
[0.93,1.91]
None
Non-opioid analgesic vs.
--1.06
[0.99,1.13]
1.14
[1.00,1.29]
*
None
Polypharmacy vs. None
--1.09
[1.02,1.17]
*
1.03
[0.90,1.19]
Note: This sample includes patients from QuintilesIMS RWD Adjudicated Claims – US, which were identified between 2007 and 2015 and had enrollment between
2006-2015. These patients were between 28-63 years old, without cancer, had complete demographic information available, and had only one opioid prescription on the
index date. Due to data use requirements, some categories were collapsed. These include insurance plan type and other opioids.
†: Doses of opioids were converted to a standardized dose (milligrams of morphine equivalent) using the Centers for Medicare and Medicaid Services conversion table.
‡: Other insurance types included fee-for-service, health savings account, and indemnity.
Significance: 0 < p < 0.001 = ***, 0.001 ≤ p 0.01 = **, 0.01 ≤ p < 0.05 = *
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Supplemental Figure 7.1.1: Receiver operator characteristic (ROC) curves for Model 1 (orange,
AUC = 0.767) and Fully Adjusted Model 2 (purple, AUC = 0.778) using the training/validation
subsamples
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Supplemental Figure 7.1.2. Receiver operator characteristic (ROC) curves for Model 1 using
the training/validation subsample (black, AUC = 0.767) and Model 1 using the test subsample
(green, AUC = 0.776).
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7.2

Supplemental Information- Chapter 3: Increased healthcare utilization and
expenditures associated with transition to chronic opioid therapy

Supplemental Table 7.2.1.
Patient characteristics before and after applying inverse probability of treatment weighting (IPTW) for patients with
incident opioid use by transition to chronic opioid therapy (COT) after first opioid prescription,
QuintilesIMS Real-World Data Adjudicated Claims Database - US, 2006-2015
Before IPTW
After IPTW
All
COT
No COT
COT
No COT
n=
n=
ChiChi%
%
p-value Sig. Wt. %
Wt. %
p-value
Sig.
3,776
16,425
square
square
29.49
<0.001 ***
1.18
0.277
Sex
Male
2,000 53.0
7,895 48.1
49.8
49.0
Female
1,776 47.0
8,530 51.9
50.2
51.0
307.36
<0.001 ***
7.61
0.055
Age
28-34
years
305
8.1
2,522 15.4
12.8
13.9
35-44
years
757 20.0
4,402 26.8
25.1
25.5
45-54
years
1,377 36.5
5,402 32.9
34.0
33.6
55-63
years
1,337 35.4
4,099 25.0
28.2
27.0
30.18
<0.001 ***
1.80
0.614
Region
East
580 15.4
2,991 18.2
17.9
17.7
Midwest
1,290 34.2
5,478 33.4
34.3
33.6
South
1,642 43.5
6,587 40.1
40.0
40.7
West
264
7.0
1,369
8.3
7.8
8.1
301.41
<0.001 ***
0.02
0.890
Highly likely chronic pain condition
Yes
112
3.0
41
0.2
0.8
0.8
No
3,664 97.0
16,384 99.8
99.2
99.2
938.71
<0.001 ***
0.88
0.347
Likely chronic pain condition
Yes
2,064 54.7
4,693 28.6
34.1
33.5
No
1,712 45.3
11,732 71.4
65.9
66.5
Note: This sample includes patients from QuintilesIMS RWD Adjudicated Claims – US, which were identified between 2007 and
2014 and had enrollment between 2006 and 2015. These patients were between 28-63 years old, without cancer, had complete
demographic information available, and had only one opioid prescription on the index date. Individual weights based on IPTW have
been used for this analysis.
Abbreviations: COT- chronic opioid therapy; Wt- weighted
Sig: 0 < p < 0.001 = ***, 0.001 ≤ p 0.01 = **, 0.01 ≤ p < 0.05 = *
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Supplemental Figure 7.2.1. Difference in unweighted average expenditures between chronic
opioid therapy (COT) and no COT transition for total (no prescription drug), emergency
department (ED), inpatient (IP), and physician costs.
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